DCN-1 modulator formulations and methods of making the same
Formulations of Compound 1 with diluents, disintegrants, binders, and lubricants provide effective treatment for sickle cell disease and thalassemia, addressing the inadequacies of existing therapies.
Patent Information
- Application Number
- PCT/US2026/026475
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-05
- Filing Date
- 2026-05-04
- Publication Date
- 2026-11-12
AI Technical Summary
There is a need for therapeutic agents and methods to treat hemoglobin-related disorders such as sickle cell disease and thalassemia, as existing treatments are inadequate in addressing the complications associated with these conditions.
Pharmaceutical compositions comprising Compound 1, or a solvate or pharmaceutically acceptable salt thereof, combined with diluents, disintegrants, binders, lubricants, and optionally surfactants, are formulated into unit dosage forms to treat hemoglobin-related disorders.
The compositions effectively target and treat sickle cell disorders and thalassemia by improving the delivery and efficacy of Compound 1, enhancing its therapeutic impact on hemoglobin-related conditions.
Smart Images

Figure US2026026475_12112026_PF_FP_ABST
Abstract
Description
DCN-1 MODULATOR FORMULATIONS AND METHODS OF MAKING THE SAMECROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application No. 63 / 800,187 filed on May 5, 2025, the entirety of which is incorporated herein by reference.TECHNICAL FIELD OF THE INVENTION
[0002] The present invention relates to pharmaceutical compositions of a DCN-1 modulator and to methods of making the compositions. The invention also provides methods of treating disorders using the pharmaceutical compositions.BACKGROUND OF THE INVENTION
[0003] Hemoglobinopathies are diseases that affect hemoglobin that include sickle cell disease and thalassemia. Sickle cell disease or disorder is a group of inherited red blood cell disorders that affect hemoglobin and can block blood flow to the body. Specifically, a defective beta hemoglobin chain in sickle cell patients twists and changes the shape of each red blood cell from a doughnutlike shape into a “sickled” or croissant shape that can clog small blood vessels and prevent the delivery of oxygen around the body. Sickle-cell disease is characterized by various acute and chronic complications, which are associated with significant morbidity and mortality in an afflicted subject. Thalassemia is also an inherited red blood cell disorder that is caused by a defect in the beta-globin gene, controlling the production of the beta-globin chains of hemoglobin. Accordingly, a patient suffering from thalassemia can’t make enough normal hemoglobin and thus has relatively fewer red blood cells and lower blood oxygen levels than people who do not suffer from the disease. Thalassemia patients may not make enough of either or both of the alpha or beta proteins in hemoglobin.
[0004] The cullin family of ubiquitination E3s are the most well-characterized substrates of neddylation. Upon neddylation, the cullins constellate the cullin-RING E3 UB ligase family (CRLs), which has approximately 300 members. The CRLs regulate diverse biological processes including cell cycle, signal transduction, DNA replication, and viral modulation. CRL dysfunction is implicated in a number of human diseases, including cancer. Drug discovery efforts targeting Page 1 of 114335847364 CENC-013 / 01WO 360899-2047the CRLs and the associated proteasomal protein degradation machinery have been extensive and continue to grow. The neddylation pathway has been successfully targeted by MLN4924 (Pevonedistat), an inhibitor of NEDD8’s El enzyme, that completely blocks NEDD8 ligation to substrates. MLN4924 is currently being tested in oncology clinical trials. An inhibitor of the COP9 signalosome, responsible for de-neddylation of the CRLs, has been reported and also displays antitumor activity. Defective in cullin neddylation 1 (DCN-1) is a protein that interacts with cullins and is required for neddylation. DCN-1 is also known as DCUN1D1, DCNL1 or Squamous Cell Carcinoma-related Oncogene (SCCRO). DCN1 is the most well characterized isoform due to its common amplification as part of a large 3q26.3 amplicon in squamous cell carcinomas (SCC) and other tumors. DCN1 amplification in SCC negatively correlates with cause-specific survival, suggesting that targeting DCN1 may be of clinical utility in cancers. Its role in other diseases remains under-explored.
[0005] There remains a need to find therapeutic agents, methods, and therapies for the treatment of hemoglobin-related disorders including sickle cell disorders, diseases and conditions and thalassemia. The present invention fulfils this need and provides other related advantages.SUMMARY OF THE INVENTION
[0006] In one aspect, the present disclosure provides pharmaceutical compositions, formulations, and unit dosage forms comprising:(a) Compound 1:or a solvate or a pharmaceutically acceptable salt thereof;(b) one or more diluents;(c) one or more disintegrants;Page l of 114335847364 CENC-013 / 01WO 360899-2047(d) one or more binders;(e) one or more lubricants; and(f) optionally, one or more surfactants.
[0007] In another aspect, the disclosure provides a method of making a unit dosage form comprising:(a) Compound 1 :F1or a solvate or a pharmaceutically acceptable salt thereof;(b) one or more diluents;(c) one or more disintegrants;(d) one or more binders;(e) one or more lubricants; and(f) optionally, one or more surfactants.
[0008] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form comprises:(a) about 1-7 mg of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 35-70 mg of a first diluent comprising mannitol;(c) about 35-70 mg of a second diluent comprising microcrystalline cellulose;(d) about 1-10 mg of a disintegrant comprising a pharmaceutically acceptable salt of starch glycolate;(e) about 1-10 mg of a binder comprising hydroxypropyl methylcellulose;(f) about 0.5-5 mg of a lubricant comprising stearic acid or a pharmaceutically acceptable salt thereof; andPage 3 of 114335847364 CENC-013 / 01WO 360899-2047(g) optionally, about 0.5-5 mg of a surfactant comprising a pharmaceutically acceptable salt of dodecylsulfate.
[0009] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form comprises:(a) about 1-7 mg of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 35-70 mg of a first diluent such as mannitol;(c) about 35-70 mg of a second diluent such as microcrystalline cellulose;(d) about 1-10 mg of a disintegrant such as sodium starch glycolate;(e) about 1-10 mg of a binder such as hydroxypropyl methylcellulose;(f) about 0.5-5 mg of a lubricant such as magnesium stearate; and(g) optionally, about 0.5-5 mg of a surfactant such as sodium lauryl sulfate.
[0010] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form comprises:(a) about 20-70 mg of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 15-50 mg of a first diluent comprising mannitol;(c) about 15-50 mg of a second diluent comprising microcrystalline cellulose;(d) about 1-10 mg of a disintegrant comprising a pharmaceutically acceptable salt of starch glycol ate;(e) about 1-10 mg of a binder comprising hydroxypropyl methylcellulose; and (f) about 0.5-5 mg of a lubricant comprising stearic acid or a pharmaceutically acceptable salt thereof.
[0011] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form comprises:(a) about 20-70 mg of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 15-50 mg of a first diluent such as mannitol;(c) about 15-50 mg of a second diluent such as microcrystalline cellulose;(d) about 1-10 mg of a disintegrant such as sodium starch glycolate;(e) about 1-10 mg of a binder such as hydroxypropyl methylcellulose; andPage 4 of 114335847364 CENC-013 / 01WO 360899-2047(f) about 0.5-5 mg of a lubricant such as magnesium stearate.
[0012] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form comprises:(a) about 100-280 mg of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 70-100 mg of a first diluent comprising mannitol;(c) about 70-100 mg of a second diluent comprising microcrystalline cellulose;(d) about 5-20 mg of a disintegrant comprising pharmaceutically acceptable salt of starch glycol ate;(e) about 5-20 mg of a binder comprising hydroxypropyl methylcellulose; and (f) about 2-10 mg of a lubricant comprising stearic acid or a pharmaceutically acceptable salt thereof.
[0013] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form comprises:(a) about 100-280 mg of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 70-100 mg of a first diluent such as mannitol;(c) about 70-100 mg of a second diluent such as microcrystalline cellulose;(d) about 5-20 mg of a disintegrant such as sodium starch glycolate;(e) about 5-20 mg of a binder such as hydroxypropyl methylcellulose; and(f) about 2-10 mg of a lubricant such as magnesium stearate.
[0014] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form comprises one of the following %w / w and mg / unit of ingredients shown below.mg / unitIngredient %w / w5 mgIntra granularCompound 1 5.0 5.0Mannitol 44.0 44.0Microcrystalline Cellulose 44.0 44.0Sodium Starch Glycolate 3.0 3.0Binder SolutionPage 5 of 114335847364 CENC-013 / 01WO 360899-2047mg / unitIngredient %w / w5 mgHydroxypropyl3.0 3.0MetliylcelluloseExtra granularMagnesium Stearate 1.0 1.0Total 100.0 100.0Capsule ShellEmpty Hard Gelatin1 CAP 48.00Capsules, 3#
[0015] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form comprises one of the following %w / w and mg / unit of ingredients shown below.mg / unitIngredient w / w %50 mg 200 mgIntra granularCompound 1 50.0 50.0 200.0Mannitol 21.5 21.5 86.0Microcrystalline21.5 21.5 86.0CelluloseSodium Starch Glycolate 3.0 3.0 12.0Binder SolutionHydroxypropyl3.0 3.0 12.0MethylcelluloseExtra granularMagnesium Stearate 1.0 1.0 4.0Total 100.0 100.0 400.0Capsule ShellEmpty Hard Gelatin1 CAP 48.00 N / ACapsules, 3#Page 6 of 114335847364 CENC-013 / 01WO 360899-2047mg / unitIngredient w / w %50 mg 200 mgEmpty Hard Gelatin1 CAP N / A 118.00Capsules, 00#BRIEF DESCRIPTION OF THE FIGURES
[0016] FIG. 1 depicts the TGA and DSC for Form C of Compound 1.
[0017] FIG. 2 depicts the XRPD for Form C of Compound 1.
[0018] FIG.3 depicts a flow chart of a formulation process.DETAILED DESCRIPTION
[0019] The invention provides pharmaceutical compositions comprising Compound 1, or a solvate or a pharmaceutically acceptable salt thereof, and their use in treating hemoglobin-related disorders including sickle cell disorders, diseases, and conditions, and thalassemia. The present invention further provides methods of making such pharmaceutical compositions, such as those described below. The practice of the present invention employs, unless otherwise indicated, conventional techniques of organic chemistry, pharmacology, molecular biology (including recombinant techniques), cell biology, biochemistry, and immunology. Such techniques are explained in the literature, such as in “Comprehensive Organic Synthesis” (B.M. Trost & I. Fleming, eds., 1991-1992); “Handbook of experimental immunology” (D M. Weir & C.C. Blackwell, eds.); “Current protocols in molecular biology” (F.M. Ausubel et al., eds., 1987, and periodic updates); and “Current protocols in immunology” (J.E. Coligan et al., eds., 1991), each of which is herein incorporated by reference in its entirety.
[0020] Various aspects of the invention are set forth below in sections; however, aspects of the invention described in one particular section are not to be limited to any particular section. Further, when a variable is not accompanied by a definition, the previous definition of the variable controls1. Definitions
[0021] Formulations and methods of the present invention include those described generally above, and are further illustrated by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise indicated. For purposes of thePage 7 of 114335847364 CENC-013 / 01WO 360899-2047present disclosure, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75thEd. Additionally, general principles of organic chemistry are described in Organic Chemistry, Thomas Sorrell, University Science Books, Sausalito: 1999, and March ’s Advanced Organic Chemistry, 5thEd., Ed.: Smith, M.B. and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.
[0022] The term “aliphatic” or “aliphatic group,” as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as “carbocycle,” “cycloaliphatic” or “cycloalkyl”), that has a single point of attachment to the rest of the molecule. Unless otherwise specified, aliphatic groups contain 1-6 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-5 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms. In some embodiments, “cycloaliphatic” (or “carbocycle” or “cycloalkyl”) refers to a monocyclic C3-C6 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
[0023] The term “heteroatom” means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2 / 7-pyrrolyl), NH (as in pyrrolidinyl) or NR (as in N-substituted pyrrolidinyl)).
[0024] The term “unsaturated,” as used herein, means that a moiety has one or more units of unsaturation.
[0025] The term “aryl” used alone or as part of a larger moiety as in “aralkyl,” “aralkoxy,” or “aryloxyalkyl,” refers to monocyclic or bicyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the systemPage 8 of 114335847364 CENC-013 / 01WO 360899-2047contains 3 to 7 ring members. The term “aryl” may be used interchangeably with the term “aryl ring.” In some embodiments, the term “aryl” used alone or as part of a larger moiety as in “aralkyl,” “aralkoxy,” or “aryloxyalkyl,” refers to monocyclic and bicyclic ring systems having a total of five to 10 ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains three to seven ring members. In certain embodiments of the compounds, “aryl” refers to an aromatic ring system which includes, but not limited to, phenyl, biphenyl, naphthyl, anthracyl and the like, which may bear one or more substituents. Also included within the scope of the term “aryl,” as it is used herein, is a group in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like.
[0026] The terms “heteroaryl” and “heteroar-,” used alone or as part of a larger moiety, e.g., “heteroaralkyl,” or “heteroaralkoxy,” refer to groups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms. The term “heteroatom” refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen. Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. The terms “heteroaryl” and “heteroar-”, as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where the radical or point of attachment is on the heteroaromatic ring. Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 477-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-l,4-oxazin-3(4H)-one. A heteroaryl group may be mono- or bicyclic. The term “heteroaryl” may be used interchangeably with the terms “heteroaryl ring,” “heteroaryl group,” or “heteroaromatic,” any of which terms include rings that are optionally substituted. The term “heteroaralkyl” refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted.
[0027] As used herein, the terms “heterocycle,” “heterocyclyl,” “heterocyclic radical,” and “heterocyclic ring” are used interchangeably and refer to a stable 5- to 7-membered monocyclic orPage 9 of 114335847364 CENC-013 / 01WO 360899-20477- to 10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above. When used in reference to a ring atom of a heterocycle, the term "nitrogen" includes a substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur and nitrogen, the nitrogen may be N (as in 3,4-dihydro-27 / pyrrolyl), NH (as in pyrrolidinyl), or+NR (as in substituted pyrrolidinyl).
[0028] A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothiophenyl pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl. The terms “heterocycle,” “heterocyclyl,” “heterocyclyl ring,” “heterocyclic group,” “heterocyclic moiety,” and “heterocyclic radical,” are used interchangeably herein, and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 37 / indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl, where the radical or point of attachment is on the heterocyclyl ring. A heterocyclyl group may be mono- or bicyclic. The term “heterocyclylalkyl” refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.
[0029] As used herein, the term “partially unsaturated” refers to a ring moiety that includes at least one double or triple bond. The term “partially unsaturated” is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.
[0030] As used herein, the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable,Page 10 of 114335847364 CENC-013 / 01WO 360899-2047nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, besylate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, mesylate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like.
[0031] Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N (Ci 4alkyl)4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
[0032] Unless otherwise stated, structures depicted herein are also meant to include all isomeric (eg., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention.
[0033] As used herein, “about” or “approximately” in reference to a numerical value means that the stated numerical value may vary by up to 10% of the stated value. For example, “about 10” refers to a value of 9.9 to 10.1 (10 + / - 0.1).
[0034] The present disclosure contains embodiments which are stated to “comprise” items. The disclosure also contemplates analogous embodiments which “consist essentially of’ or “consist of’ said items.Page 11 of 114335847364 CENC-013 / 01WO 360899-2047
[0035] ‘ ‘Nominal particle size,” as used herein refers to a particle size representing the mass average of the particles.
[0036] “Loose bulk density,” as used herein, refers to the mass per unit volume of a loose powder.
[0037] A “solubilizer,” as used herein, may refer to one or more compounds added to the formulation that increases solubility in any given solvent system, e.g., water, organic solvents, biological fluids, simulated biological fluids, and mixtures thereof.
[0038] A “binder,” as used herein, may refer to one or more compounds that promote cohesiveness among the other components in the formulation, the binders, also called adhesives, help the other ingredients in a formulation to mix together. Tablet binders may help turn powder to granules; this may be achieved during the process of granulation.
[0039] A “surfactant,” as used herein, may refer to one or more compounds that lower the surface tension between two liquids, between a gas and a liquid, or between a liquid and a solid. Surfactants may act as detergents, wetting agents, emulsifiers, foaming agents, or dispersants.
[0040] “ Glidants,” as used herein, are additive substances that are used to enhance the flowability of a powder by reducing the interparticle friction, surface charge, and cohesion, which in turn decreases the angle of repose. They are often incorporated as a dry powder just prior to direct compression.
[0041] “ Granulation,” as used herein, refers to a process to produce larger or smaller granules or particles of a substance or mixture of substances. The process also may remove fine granules and improve flowability within the formulation. Both wet granulation and / or dry granulation may be employed. Dry granulation is achieved using only a combination of granules without the need for any liquid thereon. Slugging uses a tablet press to form large tablets that vary in weight due to the poor flowability of the formulation. The slugs created are then put through a granulator to be broken down into granules and then compressed once again for a final granulated product.
[0042] Wet granulation may be used to facilitate aggregation of particles. An adhesive usually called a binder may be incorporated in the form of a solution or suspension in a suitable liquid.
[0043] A fluid bed granulator may be used for wet granulation wherein hot air is fed into a bed lifting the granules whilst they are sprayed, granules bind together to form bridges between themselves. The initial phase of wet granulation may include the spraying of the granules, the spray rate may be varied. Wetting of the powder may then begin to form liquid bridges betweenPage 12 of 114335847364 CENC-013 / 01WO 360899-2047the granules. The process is continued until the required size granule is formed with solid bridges between the granules. Once complete granules may go to the drying process, the spraying process may be turned off and the hot air will continue to flow through the bed drying the granules. The wet granulation may be performed in a high shear wet granulator, commercially available or known to those having ordinary skill in the art, e.g., a wet granulator as described in Liu et al., “A review of high shear wet granulation for better process understanding, control and product development,” Powder Technology, 381, March 2021, Pages 204-223, the entire disclosure of which is hereby incorporated by reference. As to the drying process, such methods and apparatuses to perform the same will be known to those having ordinary skill in the art. The drying may be performed in a fluid bed dryer, e.g., as described in Srivastava et al., “Fluid Bed Technology: Overview and Parameters for Process Selection,” International Journal of Pharmaceutical Sciences and Drug Research 2010; 2(4): 236-246, the entire disclosure of which is hereby incorporated by reference.
[0044] Screen milling of the process material may be used, e.g., for example after drying. Screen milling procedures and equipment are well known to those having ordinary skill in the art, e.g., as described in Kotamarthy, L.V.G., (2018). “Understanding the effect of granulation and mill process parameters on granule critical quality attributes,” [Master’s dissertation, Rutgers University], Rutger’s Library, the entire disclosure of which is hereby incorporated by reference.
[0045] “Blending,” as used herein, refers to techniques for blending solid material well known to those of ordinary skill in the art. Such techniques and machinery for blending are described in the art, e.g., Mendez et al., “Evaluation of powder mixing operation during batch production: application to operational qualification procedure in the pharmaceutical industry.” Powder Technol. 2009;198:310-3. Harnby N. “An engineering view of pharmaceutical powder mixing.” Pharm Sci Technol Today. 2000;3:303-9. Remy B. et al., “Discrete element simulation of free flowing grains in a four-bladed mixer.” AIChE J. 2009;55:2035-48; and StieB M. “Mechanische Verfahrenstechnik — Partikeltechnologie 1.” 3rd ed. Berlin: Springer; 2009, the entire disclosures each of which are hereby incorporated by reference in their entireties.
[0046] Other methods of granulation are known to those having ordinary skill in the art, and are described in Miyazaki S et al. “Drug release from oral mucosal adhesive tablets of chitosan and sodium alginate.” Int J Pharm 1995; 118: 257-263; Selmeczi B. “The influence of the compressional force on the physical properties of tablets made by different technologicalPage 13 of 114335847364 CENC-013 / 01WO 360899-2047processes.” Arch Pharm (Weinheim) 1974; 307(10): 755-760; and Beg et al., 2021, “Handbook of Analytical Quality by Design,” Elsevier Inc., the entire disclosures each of which are hereby incorporated by reference in their entireties.2. Detailed Description of Certain Aspects of the Invention
[0047] In one aspect, the present disclosure provides pharmaceutical compositions, formulations, and unit dosage forms comprising:(a) Compound 1:F1or a solvate thereof, or a pharmaceutically acceptable salt thereof;(b) one or more diluents;(c) one or more disintegrants;(d) one or more binders;(e) one or more lubricants; and(f) optionally, one or more surfactants.
[0048] In some embodiments, the pharmaceutical compositions, formulations, and unit dosage forms consist essentially of items (b) to (e) above, with item (f) optionally present.
[0049] In one aspect, the present disclosure provides pharmaceutical compositions, formulations, and unit dosage forms consisting of:(a) Compound 1:Page 14 of 114335847364 CENC-013 / 01WO 360899-20471or a solvate thereof, or a pharmaceutically acceptable salt thereof;(b) one or more diluents;(c) one or more disintegrants;(d) one or more binders;(e) one or more lubricants; and(f) optionally, one or more surfactants.
[0050] In one aspect, the present disclosure provides pharmaceutical compositions, formulations, and unit dosage forms comprising:(a) Compound 1:1or a solvate thereof, or a pharmaceutically acceptable salt thereof;(b) one or more diluents;(c) one or more disintegrants;(d) one or more binders; and(e) one or more lubricants.Page 15 of 114335847364 CENC-013 / 01WO 360899-2047
[0051] In one aspect, the present disclosure provides pharmaceutical compositions, formulations, and unit dosage forms consisting of:(a) Compound 1:F1or a solvate thereof, or a pharmaceutically acceptable salt thereof;(b) one or more diluents;(c) one or more disintegrants;(d) one or more binders; and(e) one or more lubricants.
[0052] In some embodiments, Compound 1 is in the form of a solvate, e.g., a hydrate, or a pharmaceutically acceptable salt of such solvate. In some embodiments, Compound 1 is in the form of a free base. In some embodiments, Compound 1 is in the form of an amorphous solid. In some embodiments, Compound 1 is in the form of a crystalline solid. In some embodiments, the crystalline solid is Form C.
[0053] In certain embodiments, Compound l isa crystalline compound of polymorphic Form C, characterized in that it exhibits an X-ray powder diffraction (XRPD) pattern comprising peaks substantially as shown in FIG. 2. In certain embodiments, Compound l is a crystalline compound of polymorphic Form C, characterized by TGA and DSC patterns as shown in FIG. 1. Any alternative solid form may be used in the formulations of the invention; for example, amorphous forms, crystalline form other than Form C, or mixtures thereof.
[0054] In certain embodiments, Compound 1 is amorphous. In some embodiments, Compound 1 is as a hydrate. In some embodiments, Compound 1 is as a monohydrate.
[0055] In some embodiments, the diluent is selected from mannitol, microcrystalline cellulose, sucrose, lactose, starch, magnesium stearate, sorbitol, and xylitol.Page 16 of 114335847364 CENC-013 / 01WO 360899-2047
[0056] In some embodiments, the diluent comprises mannitol. In some embodiments, the diluent comprises mannitol PEARLITOL™ 50C. In some embodiments, the diluent comprises cellulose. In some embodiments, the cellulose is microcrystalline cellulose. In some embodiments, the diluent comprises microcrystalline cellulose VIVAPUR™ 101. In some embodiment the diluent comprises a nominal particle size between about 10 mm to about 20 mm, about 20 mm to about 30 mm, about 30 mm to about 40 mm, about 40 mm to about 50 mm, about 50 mm to about 60 mm, about 60 mm to about 70 mm, or about 70 mm to about 80 mm. In some embodiments, the diluent comprises a nominal particle size of about 50 mm. In some embodiments, the diluent comprises a moisture content between about 0.5%w / w to about l%w / w, about l%w / w to about 1.5%w / w, about 1.5%w / w to about 2%w / w, about 2%w / w to about 2.5%w / w, about 2.5%w / w to about 3%w / w, about 3%w / w to about 3.5%w / w, about 3.5%w / w to about 4%w / w, about 4%w / w to about 4.5%w / w, or about 4.5%w / w to about 5%w / w. In some embodiments, the diluent comprises a moisture content between about 3%w / w to about 5%w / w. In some embodiments, the diluent comprises a loose bulk density between about 0.1 g / cm3to about 0.15 g / cm3, about 0.15 g / cm3to about 0.2 g / cm3, about 0.2 g / cm3to about 0.25 g / cm3, about 0.25 g / cm3to about 0.3 g / cm3, about 0.3 g / cm3to about 0.35 g / cm3, about 0.35 g / cm3to about 0.4 g / cm3, about 0.4 g / cm3to about 0.45 g / cm3, or about 0.45 g / cm3to about 0.5 g / cm3. In some embodiments, the diluent comprises a loose bulk density between about 0.26 g / cm3to about 0.31 g / cm3.
[0057] In some embodiments, the microcrystalline cellulose has an average molecular weight between about 10,000 Da and about 25,000 Da, about 25,000 Da and about 50,000 Da, about 50,000 Da and about 60,000 Da, or about 60,000 Da and about 80,000 Da.
[0058] In some embodiments, the disintegrant is an alkali metal starch glycolate, crospovidone, croscarmellose, or a pharmaceutically acceptable salt thereof, or a combination thereof. In some embodiments, the disintegrant is an alkali metal starch glycolate. In some embodiments, the disintegrant is a pharmaceutically acceptable salt of starch glycolate. In some embodiments, the disintegrant is sodium starch glycolate. In some embodiments, the disintegrant is sodium starch glycolate VIVASTAR™ P. In some embodiments, the disintegrant is croscarmellose or a pharmaceutically acceptable salt thereof. In some embodiments, the disintegrant is an alkali metal croscarmellose. In some embodiments, the disintegrant is crospovidone.
[0059] In some embodiments, the binder is hydroxypropyl methylcellulose, polyvinylpyrrolidone, hydroxypropyl cellulose, or a combination thereof. In some embodiments,Page 17 of 114335847364 CENC-013 / 01WO 360899-2047the binder is hydroxypropyl methylcellulose. In some embodiments, the binder is hydroxypropyl methylcellulose METHOCEL™ E5 PREMIUM LV. In some embodiments, the binder is polyvinylpyrrolidone. In some embodiments, the binder is hydroxypropyl cellulose. In some embodiments, the binder is a combination of polyvinylpyrrolidone and hydroxypropyl cellulose.
[0060] In some embodiments, the lubricant is stearic acid or a pharmaceutically acceptable salt thereof. In some embodiments, the lubricant is magnesium stearate. In some embodiments, the lubricant is magnesium stearate LIGAMED™ MF-2-V-MB.
[0061] In some embodiments, the surfactant is selected from sodium lauryl sulfate, polyoxyethylene (20) sorbitan monolaurate (e.g., Tween-20), polyoxyethylene (20) sorbitan monooleate (e.g., Tween-80), and sodium dodecyl sulfate. In some embodiments, the surfactant is sodium lauryl sulfate. In some embodiments, the surfactant is sodium lauryl sulfate KOLLIPHOR™. In some embodiments, the surfactant is polyoxyethylene (20) sorbitan monolaurate (e.g., Tween-20). In some embodiments, the surfactant is polyoxyethylene (20) sorbitan monooleate (e.g., Tween-80). In some embodiments, the surfactant is a pharmaceutically acceptable salt of dodecyl sulfate. In some embodiments, the surfactant is sodium dodecyl sulfate.
[0062] In some embodiments, the pharmaceutical composition further comprises water.
[0063] In one aspect, the present disclosure provides pharmaceutical compositions, formulations, and unit dosage forms comprising:(a) Compound 1:F1;(b) a diluent comprising mannitol and microcrystalline cellulose;(c) one or more disintegrants;(d) one or more binders;(e) one or more lubricants; andPage 18 of 114335847364 CENC-013 / 01WO 360899-2047(f) optionally, one or more surfactants.
[0064] In one aspect, the present disclosure provides pharmaceutical compositions, formulations, and unit dosage forms comprising:(a) Compound 1:F1;(b) a diluent comprising mannitol and microcrystalline cellulose;(c) sodium starch glycolate;(d) one or more binders;(e) one or more lubricants; and(f) optionally, one or more surfactants.
[0065] In one aspect, the present disclosure provides pharmaceutical compositions, formulations, and unit dosage forms comprising:(a) Compound 1:F1;(b) a diluent comprising mannitol and microcrystalline cellulose;(c) sodium starch glycolate;(d) hydroxypropyl methylcellulose;Page 19 of 114335847364 CENC-013 / 01WO 360899-2047(e) one or more lubricants; and(f) optionally, one or more surfactants.
[0066] In one aspect, the present disclosure provides pharmaceutical compositions, formulations, and unit dosage forms comprising:(a) Compound 1:(b) a diluent comprising mannitol and microcrystalline cellulose;(c) sodium starch glycolate;(d) hydroxypropyl methylcellulose;(e) magnesium stearate; and(f) optionally, one or more surfactants.
[0067] In one aspect, the present disclosure provides pharmaceutical compositions, formulations, and unit dosage forms comprising:(a) Compound 1:1;(b) a diluent comprising mannitol and microcrystalline cellulose;(c) sodium starch glycolate;Page 20 of 114335847364 CENC-013 / 01WO 360899-2047(d) hydroxypropyl methylcellulose;(e) magnesium stearate; and(f) optionally, sodium lauryl sulfate.
[0068] In one aspect, the present disclosure provides pharmaceutical compositions, formulations, and unit dosage forms comprising:(a) Compound 1 :F1;(b) a diluent comprising mannitol and microcrystalline cellulose;(c) sodium starch glycolate;(d) hydroxypropyl methylcellulose; and(e) magnesium stearate.
[0069] In one aspect, the present disclosure provides pharmaceutical compositions, formulations, and unit dosage forms consisting of:(a) Compound 1:F1;(b) a diluent comprising mannitol and microcrystalline cellulose;(c) sodium starch glycolate;Page 21 of 114335847364 CENC-013 / 01WO 360899-2047(d) hydroxypropyl methylcellulose; and(e) magnesium stearate.
[0070] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form comprises:(a) about 1-7 mg of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 35-70 mg of a first diluent comprising mannitol;(c) about 35-70 mg of a second diluent comprising microcrystalline cellulose;(d) about 1-10 mg of a disintegrant comprising a pharmaceutically acceptable salt of starch glycolate;(e) about 1-10 mg of a binder comprising hydroxypropyl methylcellulose;(f) about 0.5-5 mg of a lubricant comprising stearic acid or a pharmaceutically acceptable salt thereof; and(g) optionally, about 0.5-5 mg of a surfactant comprising a pharmaceutically acceptable salt of dodecyl sulfate.
[0071] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form comprises:(a) about 1-7 mg of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 35-70 mg of a first diluent such as mannitol;(c) about 35-70 mg of a second diluent such as microcrystalline cellulose;(d) about 1-10 mg of a disintegrant such as sodium starch glycolate;(e) about 1-10 mg of a binder such as hydroxypropyl methylcellulose;(f) about 0.5-5 mg of a lubricant such as magnesium stearate; and(g) optionally, about 0.5-5 mg of a surfactant such as sodium lauryl sulfate.
[0072] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form comprises:(a) about 1-10% w / w of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 30-60% w / w of a first diluent comprising mannitol;(c) about 30-60% w / w of a second diluent comprising microcrystalline cellulose;Page 22 of 114335847364 CENC-013 / 01WO 360899-2047(d) about 1-10% w / w of a disintegrant comprising a pharmaceutically acceptable salt of starch glycolate;(e) about 1-10% w / w of a binder comprising hydroxypropyl methylcellulose;(f) about 0.5-10% w / w of a lubricant comprising stearic acid or a pharmaceutically acceptable salt thereof; and(g) optionally, about 1-10% w / w of a surfactant comprising a pharmaceutically acceptable salt of dodecyl sulfate.
[0073] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form comprises:(a) about 1-10% w / w of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 30-60% w / w of a first diluent such as mannitol;(c) about 30-60% w / w of a second diluent such as microcrystalline cellulose;(d) about 1-10% w / w of a disintegrant such as sodium starch glycolate;(e) about 1-10% w / w of a binder such as hydroxypropyl methylcellulose;(f) about 0.5-10% w / w of a lubricant such as magnesium stearate; and(g) optionally, about 1-10% w / w of a surfactant such as sodium lauryl sulfate.
[0074] In some embodiments, each of (b), (c), (d), (e), (f) and (g) are distributed between granules comprising (a) and an extragranular portion of the pharmaceutical composition, formulation, or unit dosage form.
[0075] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form comprises:(a) about 1-7 mg of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 35-70 mg of a first diluent comprising mannitol;(c) about 35-70 mg of a second diluent comprising microcrystalline cellulose;(d) about 1-10 mg of a disintegrant comprising a pharmaceutically acceptable salt of starch glycol ate;(e) about 1-10 mg of a binder comprising hydroxypropyl methylcellulose; and (f) about 0.5-5 mg of a lubricant comprising stearic acid or a pharmaceutically acceptable salt thereof.Page 23 of 114335847364 CENC-013 / 01WO 360899-2047
[0076] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form comprises:(a) about 1-7 mg of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 35-70 mg of a first diluent such as mannitol;(c) about 35-70 mg of a second diluent such as microcrystalline cellulose;(d) about 1-10 mg of a disintegrant such as sodium starch glycolate;(e) about 1-10 mg of a binder such as hydroxypropyl methylcellulose; and(f) about 0.5-5 mg of a lubricant such as magnesium stearate.
[0077] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form comprises:(a) about 1-10% w / w of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 30-60% w / w of a first diluent comprising mannitol;(c) about 30-60% w / w of a second diluent comprising microcrystalline cellulose; (d) about 1-10% w / w of a disintegrant comprising a pharmaceutically acceptable salt of starch glycolate;(e) about 1-10% w / w of a binder comprising hydroxypropyl methylcellulose; and (f) about 0.5-10% w / w of a lubricant comprising stearic acid or a pharmaceutically acceptable salt thereof.
[0078] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form comprises:(a) about 1-10% w / w of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 30-60% w / w of a first diluent such as mannitol;(c) about 30-60% w / w of a second diluent such as microcrystalline cellulose;(d) about 1-10% w / w of a disintegrant such as sodium starch glycolate;(e) about 1-10% w / w of a binder such as hydroxypropyl methylcellulose; and (f) about 0.5-10% w / w of a lubricant such as magnesium stearate.Page 24 of 114335847364 CENC-013 / 01WO 360899-2047
[0079] In some embodiments, each of (b), (c), (d), (e), and (f) are distributed between granules comprising (a) and an extragranular portion of the pharmaceutical composition, formulation, or unit dosage form.
[0080] In some embodiments, the intragranular phase comprises each of (a), (b), (c), (d), and (e); and an extragranular portion comprises (f) of the pharmaceutical composition, formulation, or unit dosage form.
[0081] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form comprises:(a) about 20-70 mg of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 15-50 mg of a first diluent comprising mannitol;(c) about 15-50 mg of a second diluent comprising microcrystalline cellulose;(d) about 1-10 mg of a disintegrant comprising a pharmaceutically acceptable salt of starch glycolate;(e) about 1-10 mg of a binder comprising hydroxypropyl methylcellulose; and (f) about 0.5-5 mg of a lubricant comprising stearic acid or a pharmaceutically acceptable salt thereof.
[0082] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form comprises:(a) about 20-70 mg of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 15-50 mg of a first diluent such as mannitol;(c) about 15-50 mg of a second diluent such as microcrystalline cellulose;(d) about 1-10 mg of a disintegrant such as sodium starch glycolate;(e) about 1-10 mg of a binder such as hydroxypropyl methylcellulose; and(f) about 0.5-5 mg of a lubricant such as magnesium stearate.
[0083] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form comprises:(a) about 20-70% w / w of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 10-40% w / w of a first diluent comprising mannitol;Page 25 of 114335847364 CENC-013 / 01WO 360899-2047(c) about 10-40% w / w of a second diluent comprising microcrystalline cellulose; (d) about 1-10% w / w of a disintegrant comprising a pharmaceutically acceptable salt of starch glycolate;(e) about 1-10% w / w of a binder comprising hydroxypropyl methylcellulose; and (f) about 0.5-10% of a lubricant comprising stearic acid or a pharmaceutically acceptable salt thereof.
[0084] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form comprises:(a) about 20-70% w / w of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 10-40% w / w of a first diluent such as mannitol;(c) about 10-40% w / w of a second diluent such as microcrystalline cellulose;(d) about 1-10% w / w of a disintegrant such as sodium starch glycolate;(e) about 1-10% w / w of a binder such as hydroxypropyl methylcellulose; and (f) about 0.5-10% of a lubricant such as magnesium stearate.
[0085] In some embodiments, each of (b), (c), (d), (e), and (f) are distributed between granules comprising (a) and an extragranular portion of the pharmaceutical composition, formulation, or unit dosage form.
[0086] In some embodiments, the intragranular phase comprises each of (a), (b), (c), (d), and (e); and an extragranular portion comprises (f) of the pharmaceutical composition, formulation, or unit dosage form.
[0087] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form comprises:(a) about 100-300 mg of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 70-180 mg of a first diluent comprising mannitol;(c) about 70-180 mg of a second diluent comprising microcrystalline cellulose;(d) about 5-25 mg of a disintegrant comprising a pharmaceutically acceptable salt of starch glycolate;(e) about 5-25 mg of a binder comprising hydroxypropyl methylcellulose; andPage 26 of 114335847364 CENC-013 / 01WO 360899-2047(f) about 2-25 mg of a lubricant comprising stearic acid or a pharmaceutically acceptable salt thereof.
[0088] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form comprises:(a) about 100-300 mg of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 70-180 mg of a first diluent such as mannitol;(c) about 70-180 mg of a second diluent such as microcrystalline cellulose;(d) about 5-25 mg of a disintegrant such as sodium starch glycolate;(e) about 5-25 mg of a binder such as hydroxypropyl methylcellulose; and(f) about 2-25 mg of a lubricant such as magnesium stearate.
[0089] In some embodiments, each of (b), (c), (d), (e), and (f) are distributed between granules comprising (a) and an extragranular portion of the pharmaceutical composition, formulation, or unit dosage form.
[0090] In some embodiments, the intragranular phase comprises each of (a), (b), (c), (d), and (e); and an extragranular portion comprises (f) of the pharmaceutical composition, formulation, or unit dosage form.
[0091] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form comprises one of the following amounts or %w / w of ingredients shown below.mg / unitIngredient %w / w5 mgIntra granularCompound 1 5.0 5.0Mannitol 44.0 44.0Microcrystalline Cellulose 44.0 44.0Sodium Starch Glycolate 3.0 3.0Binder SolutionHydroxypropyl3.0 3.0MethylcelluloseExtra granularPage 27 of 114335847364 CENC-013 / 01WO 360899-2047mg / unitIngredient %w / w5 mgMagnesium Stearate 1.0 1.0Total 100.0 100.0Capsule ShellEmpty Hard Gelatin1 CAP 48.00Capsules, 3#
[0092] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form comprises one of the following amounts or %w / w of ingredients shown below.mg / unitIngredient w / w %50 mg 200 mgIntra granularCompound 1 50.0 50.0 200.0Mannitol 21.5 21.5 86.0Microcrystalline21.5 21.5 86.0CelluloseSodium Starch Glycolate 3.0 3.0 12.0Binder SolutionHydroxypropyl3.0 3.0 12.0MethylcelluloseExtra granularMagnesium Stearate 1.0 1.0 4.0Total 100.0 100.0 400.0Capsule ShellEmpty Hard Gelatin1 CAP 48.00 N / ACapsules, 3#Empty Hard Gelatin1 CAP N / A 118.00Capsules, 00#
[0093] In another aspect, the present invention provides a method of manufacturing a formulation described above, comprising the steps of:Page 28 of 114335847364 CENC-013 / 01WO 360899-2047(1) dry mixing Compound 1 or a solvate or a pharmaceutically acceptable salt thereof, and one or more intragranular excipients;(2) preparing a binder solution;(3) assembling an intragranular phase by wet granulation;(4) dry granulating the mixture;(5) blending the dry granulate with one or more extragranular excipients; and(6) optionally, filling the formulation into an appropriate unit container such as capsules.
[0094] In some embodiments, compound 1, one or more diluents, disintegrants, binders and lubricants are distributed in an intragranular or extragranular phase. In some embodiments, compound 1, one or more diluents, disintegrants, and binders are distributed in an intragranular phase; and lubricants are distributed in an extragranular phase. In some embodiments, compound 1, mannitol, microcrystalline cellulose, a pharmaceutically acceptable salt of starch glycolate, and hydroxypropyl methylcellulose are distributed in an intragranular phase; and stearic acid or a pharmaceutically acceptable salt thereof is distributed in an extragranular phase. In some embodiments, compound 1, mannitol, microcrystalline cellulose, sodium starch glycolate, and hydroxypropyl methylcellulose are distributed in an intragranular phase; and magnesium stearate is distributed in an extragranular phase. In some embodiments, step (3) further comprises the use of a granulation aid. In some embodiments, the granulation aid is water.
[0095] In some embodiments, the manufacturing process is substantially as described in the flow diagram shown in FIG.3 and in the Exemplification section below.
[0096] In some embodiments, Compound 1 is in the form of a solvate, e.g., a hydrate, or a pharmaceutically acceptable salt of such solvate. In some embodiments, Compound 1 is in the form of a free base. In some embodiments, Compound 1 is in the form of an amorphous solid. In some embodiments, Compound 1 is in the form of a crystalline solid. In some embodiments, the crystalline solid is Form C.
[0097] Any alternative solid form may be used in the formulations of the invention; for example, amorphous forms, crystalline form other than Form C, or mixtures thereof.
[0098] In certain embodiments, Compound 1 is amorphous. In some embodiments, Compound l is a hydrate. In some embodiments, Compound l is a monohydrate or is partially hydrated.
[0099] In some embodiments, the diluent is selected from mannitol, microcrystalline cellulose, sucrose, lactose, starch, magnesium stearate, sorbitol, and xylitol.Page 29 of 114335847364 CENC-013 / 01WO 360899-2047
[0100] In some embodiments, the diluent comprises mannitol. In some embodiments, the diluent comprises mannitol PEARLITOL™ 50C. In some embodiments, the diluent comprises cellulose. In some embodiments, the cellulose is microcrystalline cellulose. In some embodiments, the diluent comprises microcrystalline cellulose VIVAPUR™ 101. In some embodiment the diluent comprises a nominal particle size between about 10 mm to about 20 mm, about 20 mm to about 30 mm, about 30 mm to about 40 mm, about 40 mm to about 50 mm, about 50 mm to about 60 mm, about 60 mm to about 70 mm, or about 70 mm to about 80 mm. In some embodiments, the diluent comprises a nominal particle size of about 50 mm. In some embodiments, the diluent comprises a moisture content between about 0.5%w / w to about l%w / w, about l%w / w to about 1.5%w / w, about 1.5%w / w to about 2%w / w, about 2%w / w to about 2.5%w / w, about 2.5%w / w to about 3%w / w, about 3%w / w to about 3.5%w / w, about 3.5%w / w to about 4%w / w, about 4%w / w to about 4.5%w / w, or about 4.5%w / w to about 5%w / w. In some embodiments, the diluent comprises a moisture content between about 3%w / w to about 5%w / w. In some embodiments, the diluent comprises a loose bulk density between about 0.1 g / cm3to about 0.15 g / cm3, about 0.15 g / cm3to about 0.2 g / cm3, about 0.2 g / cm3to about 0.25 g / cm3, about 0.25 g / cm3to about 0.3 g / cm3, about 0.3 g / cm3to about 0.35 g / cm3, about 0.35 g / cm3to about 0.4 g / cm3, about 0.4 g / cm3to about 0.45 g / cm3, or about 0.45 g / cm3to about 0.5 g / cm3. In some embodiments, the diluent comprises a loose bulk density between about 0.26 g / cm3to about 0.31 g / cm3.
[0101] In some embodiments, the microcrystalline cellulose has an average molecular weight between about 10,000 Da and about 25,000 Da, about 25,000 Da and about 50,000 Da, about 50,000 Da and about 60,000 Da, or about 60,000 Da and about 80,000 Da.
[0102] In some embodiments, the disintegrant is an alkali metal starch glycolate, crospovidone, croscarmellose, or a pharmaceutically acceptable salt thereof, or a combination thereof. In some embodiments, the disintegrant is an alkali metal starch glycolate. In some embodiments, the disintegrant is pharmaceutically acceptable salt of starch glycolate. In some embodiments, the disintegrant is sodium starch glycolate. In some embodiments, the disintegrant is sodium starch glycolate VIVASTAR™ P. In some embodiments, the disintegrant is croscarmellose or a pharmaceutically acceptable salt thereof. In some embodiments, the disintegrant is an alkali metal croscarmellose. In some embodiments, the disintegrant is crospovidone.
[0103] In some embodiments, the binder is hydroxypropyl methylcellulose, polyvinylpyrrolidone, hydroxypropyl cellulose, or a combination thereof. In some embodiments,Page 30 of 114335847364 CENC-013 / 01WO 360899-2047the binder is hydroxypropyl methylcellulose. In some embodiments, the binder is hydroxypropyl methylcellulose METHOCEL™ E5 PREMIUM LV. In some embodiments, the binder is polyvinylpyrrolidone. In some embodiments, the binder is hydroxypropyl cellulose. In some embodiments, the binder is a combination of polyvinylpyrrolidone and hydroxypropyl cellulose.
[0104] In some embodiments, the lubricant is stearic acid or a pharmaceutically acceptable salt thereof. In some embodiments, the lubricant is magnesium stearate. In some embodiments, the lubricant is magnesium stearate LIGAMED™ MF-2-V-MB.
[0105] In some embodiments, the surfactant is selected from sodium lauryl sulfate, polyoxyethylene (20) sorbitan monolaurate (e.g., Tween-20), polyoxyethylene (20) sorbitan monooleate (e.g., Tween-80), and sodium dodecyl sulfate. In some embodiments, the surfactant is sodium lauryl sulfate. In some embodiments, the surfactant is sodium lauryl sulfate KOLLIPHOR™. In some embodiments, the surfactant is polyoxyethylene (20) sorbitan monolaurate (e.g., Tween-20). In some embodiments, the surfactant is polyoxyethylene (20) sorbitan monooleate (e.g., Tween-80). In some embodiments, the surfactant is a pharmaceutically acceptable salt of dodecyl sulfate. In some embodiments, the surfactant is sodium dodecyl sulfate.Unit Dosage Forms
[0106] In some embodiments, the unit dosage form is in the form of a capsule or tablet. Capsules, tablets, and other unit dosage forms are described in additional detail infra. As noted above, pharmaceutical composition, formulations, and unit dosage forms may comprise:(a) Compound 1, or a solvate thereof, or a pharmaceutically acceptable salt thereof; (b) one or more diluents;(c) one or more disintegrants;(d) one or more binders;(e) one or more lubricants; and(f) optionally, one or more surfactants.
[0107] In some embodiments, the unit dosage form comprises (a), (b), (c), (d), (e), and optionally (f) as described supra. In some embodiments, the unit dosage form comprises (a), (b), (c), (d) and (e). In some embodiments, the unit dosage form consists essentially of (a), (b), (c), (d) and (e). In some embodiments, the unit dosage form consists of (a), (b), (c), (d) and (e).
[0108] In some embodiments, the unit dosage form comprises an amount of Compound 1 or a solvate or pharmaceutically acceptable salt thereof between about 1 mg to about 2.5 mg, about 2.5Page 31 of 114335847364 CENC-013 / 01WO 360899-2047mg to about 5 mg, about 5 mg to about 7.5 mg, about 7.5 mg to about 10 mg, about 10 mg to about 12.5 mg, about 12.5 mg to about 15 mg, about 15 mg to about 17.5 mg, about 17.5 mg to about 20 mg, about 20 mg to about 22.5 mg, about 22.5 mg to about 25 mg, about 25 mg to about 27.5 mg, about 27.5 mg to about 30 mg, about 30 mg to about 32.5 mg, about 32.5 mg to about 35 mg, about 35 mg to about 37.5 mg, about 37.5 mg to about 40 mg, about 40 mg to about 45 mg, about 45 mg to about 50 mg, about 50 mg to about 60 mg, about 60 mg to about 70 mg, about 70 mg to about 80 mg, about 80 mg to about 90 mg, about 90 mg to about 100 mg, about 100 mg to about 125 mg, about 125 mg to about 150 mg, about 150 mg to about 175 mg, about 175 mg to about 200 mg, about 200 mg to about 225 mg, about 225 mg to about 250 mg, about 250 mg to about 275 mg, or about 275 mg to about 300 mg. In some embodiments, the unit dosage form comprises an amount of about 5 mg. In some embodiments, the unit dosage form comprises an amount of about 50 mg. In some embodiments, the unit dosage form comprises an amount of about 250 mg.
[0109] In some embodiments, the unit dosage form comprises an amount of Compound 1 or a solvate or pharmaceutically acceptable salt thereof between about l%w / w to about 2.5%w / w, about 2.5%w / w to about 5%w / w, about 5%w / w to about 7.5%w / w, about 7.5%w / w to about 10%w / w, about 10%w / wto about 12.5%w / w, about 12.5%w / wto about 15%w / w, about 15%w / w to about 17.5%w / w, about 17.5%w / w to about 20%w / w, about 20%w / w to about 25%w / w, about 25%w / w to about 30%w / w, about 30%w / w to about 35%w / w, about 35%w / w to about 40%w / w, about 40%w / w to about 45%w / w, about 45%w / w to about 50%w / w, about 50%w / w to about 55%w / w, or about 55%w / w to about 60%w / w. In some embodiments, the unit dosage form comprises an amount of about 5%w / w. In some embodiments, the unit dosage form comprises an amount of about 50%w / w.
[0110] In some embodiments, the unit dosage form comprises an amount of (b) between about 15 mg to about 17.5 mg, about 17.5 mg to about 20 mg, about 20 mg to about 22.5 mg, about 22.5 mg to about 25 mg, about 25 mg to about 27.5 mg, about 27.5 mg to about 30 mg, about 30 mg to about 32.5 mg, about 32.5 mg to about 35 mg, about 35 mg to about 37.5 mg, about 37.5 mg to about 40 mg, about 40 mg to about 45 mg, about 45 mg to about 50 mg, about 50 mg to about 75 mg, about 75 mg to about 100 mg, about 100 mg to about 125 mg, about 125 mg to about 150 mg, about 150 mg to about 175 mg, about 175 mg to about 200 mg, or about 200 mg to about 225 mg. In some embodiments, the unit dosage form comprises an amount of (b) of about 43 mg. In some embodiments, the unit dosage form comprises an amount of (b) of about 88 mg. In somePage 32 of 114335847364 CENC-013 / 01WO 360899-2047embodiments, the unit dosage form comprises an amount of first diluent of about 21.5 mg. In some embodiments, the unit dosage form comprises an amount of second diluent of about 21.5 mg. In some embodiments, the unit dosage form comprises an amount of first diluent of about 44 mg. In some embodiments, the unit dosage form comprises an amount of second diluent of about 44 mg. In some embodiments, the unit dosage form comprises an amount of first diluent of about 88 mg. In some embodiments, the unit dosage form comprises an amount of second diluent of about 88 mg.[OHl] In some embodiments, the unit dosage form comprises an amount of (b) between about 20%w / w to about 30%w / w, about 30%w / w to about 40%w / w, about 40%w / w to about 50%w / w, about 50%w / w to about 60%w / w, about 60%w / w to about 70%w / w, about 70%w / w to about 80%w / w, or about 80%w / w to about 90%w / w. In some embodiments, the unit dosage form comprises an amount of (b) of about 43%w / w. In some embodiments, the unit dosage form comprises an amount of (b) of about 88%w / w. In some embodiments, the unit dosage form comprises an amount of first diluent of about 21.5%w / w. In some embodiments, the unit dosage form comprises an amount of second diluent of about 21.5%w / w. In some embodiments, the unit dosage form comprises an amount of first diluent of about 44%w / w. In some embodiments, the unit dosage form comprises an amount of second diluent of about 44%w / w.
[0112] In some embodiments, the unit dosage form comprises an amount of (c) between about 1 mg to about 2.5 mg, about 2.5 mg to about 5 mg, about 5 mg to about 7.5 mg, about 7.5 mg to about 10 mg, about 10 mg to about 12.5 mg, about 12.5 mg to about 15 mg, about 15 mg to about 17.5 mg, or about 17.5 mg to about 20 mg. In some embodiments, the unit dosage form comprises an amount of (c) of about 3 mg. In some embodiments, the unit dosage form comprises an amount of (c) of about 12 mg.
[0113] In some embodiments, the unit dosage form comprises an amount of (c) between about 2%w / w to about 5%w / w, about 5%w / w to about 10%w / w, or about 10%w / w to about 15%w / w. In some embodiments, the unit dosage form comprises an amount of (c) of about 3%w / w.
[0114] In some embodiments, the unit dosage form comprises an amount of (d) between about 1 mg to about 2 mg, about 2 mg to about 3 mg, about 3 mg to about 4 mg, about 4 mg to about 5 mg, about 5 mg to about 6 mg, about 6 mg to about 7 mg, about 7 mg to about 8 mg, about 8 mg to about 9 mg, about 9 mg to about 10 mg, about 11 mg to about 12 mg, about 12 mg to about 13 mg, about 13 mg to about 14 mg, about 14 mg to about 15 mg, about 15 mg to about 16 mg, aboutPage 33 of 114335847364 CENC-013 / 01WO 360899-204716 mg to about 17 mg, about 17 mg to about 18 mg, about 18 mg to about 19 mg, about 19 mg to about 20 mg. In some embodiments, the unit dosage form comprises an amount of (d) of about 3 mg. In some embodiments, the unit dosage form comprises an amount of (d) of about 12 mg.
[0115] In some embodiments, the unit dosage form comprises an amount of (d) between about 0.25%w / w to about 0.5%w / w, about 0.5%w / w to about 0.75%w / w, about 0.75%w / w to about l%w / w, about l%w / w to about 1.25%w / w, about 1.25%w / w to about 1.5%w / w, about 1.5%w / w to about 1.75%w / w, about 1.75%w / w to about 2%w / w, about 2%w / w to about 2.5%w / w, about 2.5%w / w to about 3%w / w, about 3%w / w to about 3.5%w / w, or about 3.5%w / w to about 4%w / w. In some embodiments, the unit dosage form comprises an amount of (d) of about 3%w / w.
[0116] In some embodiments, the unit dosage form comprises an amount of (e) between about 0.5 mg to about 1 mg, about 1 mg to about 2.5 mg, about 2.5 mg to about 5 mg, about 5 mg to about 7.5 mg, or about 7.5 mg to about 10 mg. In some embodiments, the unit dosage form comprises an amount of (e) of about 1 mg. In some embodiments, the unit dosage form comprises an amount of (e) of about 4 mg.
[0117] In some embodiments, the unit dosage form comprises an amount of (e) between about 0.5%w / w to about l%w / w, about l%w / w to about 1.5%w / w, or about 1.5%w / w to about 2%w / w. In some embodiments, the unit dosage form comprises an amount of (e) of about l%w / w.
[0118] In some embodiments, the unit dosage form comprises:(a) about 1-7 mg of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 35-70 mg of a first diluent such as mannitol;(c) about 35-70 mg of a second diluent such as microcrystalline cellulose;(d) about 1-10 mg of a disintegrant such as sodium starch glycolate;(e) about 1-10 mg of a binder such as hydroxypropyl methylcellulose; and(f) about 0.5-5 mg of a lubricant such as magnesium stearate.
[0119] In some embodiments, the unit dosage form comprises:(a) about 1-10% w / w of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 30-60% w / w of a first diluent such as mannitol;(c) about 30-60% w / w of a second diluent such as microcrystalline cellulose;(d) about 1-10% w / w of a disintegrant such as sodium starch glycolate;Page 34 of 114335847364 CENC-013 / 01WO 360899-2047(e) about 1-10% w / w of a binder such as hydroxypropyl methylcellulose; and (f) about 0.5-10% w / w of a lubricant such as magnesium stearate.
[0120] In some embodiments, the unit dosage form comprises:(a) about 20-70 mg of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 15-50 mg of a first diluent such as mannitol;(c) about 15-50 mg of a second diluent such as microcrystalline cellulose;(d) about 1-10 mg of a disintegrant such as sodium starch glycolate;(e) about 1-10 mg of a binder such as hydroxypropyl methylcellulose; and(f) about 0.5-5 mg of a lubricant such as magnesium stearate.
[0121] In some embodiments, the unit dosage form comprises:(a) about 20-70% w / w of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 10-40% w / w of a first diluent such as mannitol;(c) about 10-40% w / w of a second diluent such as microcrystalline cellulose;(d) about 1-10% w / w of a disintegrant such as sodium starch glycolate;(e) about 1-10% w / w of a binder such as hydroxypropyl methylcellulose; and (f) about 0.5-10% w / w of a lubricant such as magnesium stearate.
[0122] In some embodiments, the unit dosage form comprises:(a) about 1-7 mg of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 35-70 mg of a first diluent such as mannitol;(c) about 35-70 mg of a second diluent such as microcrystalline cellulose;(d) about 1-10 mg of a disintegrant such as sodium starch glycolate;(e) about 1-10 mg of a binder such as hydroxypropyl methylcellulose; and(f) about 0.5-5 mg of a lubricant such as magnesium stearate.
[0123] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form of any embodiment herein comprises granules, wherein the pharmaceutical composition, formulation, or unit dosage form comprises intragranular and extragranular components as follows:Page 35 of 114335847364 CENC-013 / 01WO 360899-2047(a) about 20-70 mg of intragranular Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 15-50 mg of intragranular mannitol;(c) about 15-50 mg of intragranular microcrystalline cellulose;(d) about 1-10 mg of intragranular sodium starch glycolate;(e) about 1-10 mg of intragranular hydroxypropyl methylcellulose; and(f) about 0.5-5 mg of extragranular lubricant such as magnesium stearate.
[0124] In some embodiments, the pharmaceutical composition, formulation, or unit dosage form of any embodiment herein comprises granules, wherein the pharmaceutical composition, formulation, or unit dosage form comprises intragranular and extragranular components as follows:(a) about 100-300 mg of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 70-180 mg of a first diluent such as mannitol;(c) about 70-180 mg of a second diluent such as microcrystalline cellulose;(d) about 5-25 mg of a disintegrant such as sodium starch glycolate;(e) about 5-25 mg of a binder such as hydroxypropyl methylcellulose; and(f) about 2-25 mg of a lubricant such as magnesium stearate.
[0125] In some embodiments, Compound 1 is in the form of a solvate, e.g., a hydrate, or a pharmaceutically acceptable salt of such solvate. In some embodiments, Compound 1 is in the form of a free base. In some embodiments, Compound 1 is in the form of an amorphous solid. In some embodiments, Compound 1 is in the form of a crystalline solid. In some embodiments, the crystalline solid is Form C.
[0126] Any alternative solid form may be used in the formulations of the invention; for example, amorphous forms, crystalline form other than III, or mixtures thereof.
[0127] In certain embodiments, Compound 1 amorphous. In some embodiments, Compound 1 is a hydrate. In some embodiments, Compound l is a monohydrate or partial hydrate.Methods of Formulation ProductionPage 36 of 114335847364 CENC-013 / 01WO 360899-2047
[0128] In one aspect, the present disclosure provides a method of producing a pharmaceutical composition, formulation, or unit dosage form, the method comprising wet granulation of a mixture comprising Compound 1:F1or a solvate thereof, or a pharmaceutically acceptable salt thereof; and one or more solubilizers.
[0129] In some embodiments, the method comprises:(1) wet granulation of the mixture; and(2) drying the mixture.
[0130] In some embodiments, the method comprises:(1) wet granulation of the mixture;(2) drying the mixture; and(3) dry milling the mixture.
[0131] In some embodiments, the method comprises:(1) wet granulation of the mixture;(2) drying the mixture;(3) dry milling the mixture; and(4) blending the mixture.
[0132] In some embodiments, the method comprises:(1) wet granulation of the mixture;(2) drying the mixture;(3) dry milling the mixture;(4) blending the mixture; and(5) encapsulating the mixture.Page 37 of 114335847364 CENC-013 / 01WO 360899-2047
[0133] In another aspect, the present invention provides a method of manufacturing a formulation described above, comprising the steps of:(1) dry mixing Compound 1 or a solvate or a pharmaceutically acceptable salt thereof, and one or more intragranular excipients;(2) preparing a binder solution;(3) assembling an intragranular phase by wet granulation;(4) dry granulating the mixture;(5) blending the dry granulate with one or more extragranular excipients; and(6) optionally, filling the formulation into an appropriate unit container such as capsules.
[0134] In some embodiments, the mixture comprises:(a) Compound 1;(b) one or more diluents;(c) one or more disintegrants;(d) one or more binders;(e) one or more lubricants; and(g) optionally, one or more surfactants.
[0135] In some embodiments, the mixture comprises:(a) Compound 1;(b) one or more diluents;(c) one or more disintegrants;(d) one or more binders; and(e) one or more lubricants.
[0136] In some embodiments, the mixture comprises:(a) about 1-7 mg of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 35-70 mg of a first diluent such as mannitol;(c) about 35-70 mg of a second diluent such as microcrystalline cellulose;(d) about 1-10 mg of a disintegrant such as sodium starch glycolate;(e) about 1-10 mg of a binder such as hydroxypropyl methylcellulose; and(f) about 0.5-5 mg of a lubricant such as magnesium stearate.
[0137] In some embodiments, the mixture comprises:Page 38 of 114335847364 CENC-013 / 01WO 360899-2047(a) about 1-10% w / w of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 30-60% w / w of a first diluent such as mannitol;(c) about 30-60% w / w of a second diluent such as microcrystalline cellulose;(d) about 1-10% w / w of a disintegrant such as sodium starch glycolate;(e) about 1-10% w / w of a binder such as hydroxypropyl methylcellulose; and (f) about 0.5-10% w / w of a lubricant such as magnesium stearate.
[0138] In some embodiments, each of (b), (c), (d), (e), and (f) are distributed between granules comprising (a) and an extragranular portion of the pharmaceutical composition, formulation, or unit dosage form.
[0139] In some embodiments, the intragranular phase comprises each of (a), (b), (c), (d), and (e); and an extragranular portion comprises (f) of the pharmaceutical composition, formulation, or unit dosage form.
[0140] In some embodiments, the mixture comprises:(a) about 20-70 mg of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 15-50 mg of a first diluent such as mannitol;(c) about 15-50 mg of a second diluent such as microcrystalline cellulose;(d) about 1-10 mg of a disintegrant such as sodium starch glycolate;(e) about 1-10 mg of a binder such as hydroxypropyl methylcellulose; and(f) about 0.5-5 mg of a lubricant such as magnesium stearate.
[0141] In some embodiments, the mixture comprises:(a) about 20-70% w / w of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 10-40% w / w of a first diluent such as mannitol;(c) about 10-40% w / w of a second diluent such as microcrystalline cellulose;(d) about 1-10% w / w of a disintegrant such as sodium starch glycolate;(e) about 1-10% w / w of a binder such as hydroxypropyl methylcellulose; and (f) about 0.5-10% of a lubricant such as magnesium stearate.Page 39 of 114335847364 CENC-013 / 01WO 360899-2047
[0142] In some embodiments, each of (b), (c), (d), (e), and (f) are distributed between granules comprising (a) and an extragranular portion of the pharmaceutical composition, formulation, or unit dosage form.
[0143] In some embodiments, the intragranular phase comprises each of (a), (b), (c), (d), and (e); and an extragranular portion comprises (f) of the pharmaceutical composition, formulation, or unit dosage form.
[0144] In some embodiments, the mixture comprises:(a) about 100-300 mg of Compound 1 or a solvate or a pharmaceutically acceptable salt thereof;(b) about 70-180 mg of a first diluent such as mannitol;(c) about 70-180 mg of a second diluent such as microcrystalline cellulose;(d) about 5-25 mg of a disintegrant such as sodium starch glycolate;(e) about 5-25 mg of a binder such as hydroxypropyl methylcellulose; and(f) about 2-25 mg of a lubricant such as magnesium stearate.
[0145] In some embodiments, each of (b), (c), (d), (e), and (f) are distributed between granules comprising (a) and an extragranular portion of the pharmaceutical composition, formulation, or unit dosage form.
[0146] In some embodiments, the intragranular phase comprises each of (a), (b), (c), (d), and (e); and an extragranular portion comprises (f) of the pharmaceutical composition, formulation, or unit dosage form.Uses of Pharmaceutical Compositions
[0147] Compound 1 and compositions described herein are generally useful in treating disorders, diseases, and conditions associated with DCN-1. In some embodiments, modulating DCN-1 is inhibiting or reducing the activity of DCN-1. Without being limited to a specific mechanism, as shown herein, inhibiting or reducing the activity of DCN-1 results in reduced neddylation and other downstream effects. It has also been found that the Compound 1 and compositions described herein can modulate DCN-2 (also referred to herein as DCN2) and are useful in treating disorders, diseases, and conditions associated with DCN-2. In some embodiments, modulating DCN-2 is inhibiting or reducing the activity of DCN-2. Without being limited to a specific mechanism, as shown herein, inhibiting or reducing the activity of DCN-2 results in reduced neddylation and other downstream effects.Page 40 of 114335847364 CENC-013 / 01WO 360899-2047
[0148] In one aspect, the present disclosure provides a method of modulating the activity of DCN-1 in vitro or in vivo, comprising contacting DCN-1 with Compound 1 and compositions described herein, or a pharmaceutically acceptable salt thereof. In one aspect, the present disclosure provides a method of modulating the activity of DCN-2 in vitro or in vivo, comprising contacting DCN-2 with Compound 1 and compositions described herein, or a pharmaceutically acceptable salt thereof.
[0149] In some embodiments, the present disclosure provides a method of modulating the activity of DCN-1 and / or DCN-2 in a subject, comprising administering to the subject Compound 1 and compositions described herein, or a pharmaceutically acceptable salt thereof.
[0150] In one aspect, the disease, disorder, or condition associated with DCN-1 or DCN-2 is a hemoglobinopathy such as sickle cell disorder or disease, or thalassemia disorder or disease.
[0151] In some embodiments, the disease, disorder, or condition associated with DCN-1 or DCN- 2 is selected from one of those described in He et al. (Int Journal of Biological Macromolecules 227, 2024, 134541). In some embodiments, the disease, disorder, or condition associated with DCN-1 or DCN-2 is cancer (e.g., non-small cell lung cancer or gastric cancer), liver injury (e.g., non-alcoholic fatty liver disease), cardiac remodeling (e.g., atherosclerosis) or neurodegenerative disease (e.g., frontotemporal lobar degeneration). In some embodiments, the disease, disorder, or condition associated with DCN-1 or DCN-2 is characterized by overexpression of DCN-1 and / or DCN-2. In some embodiments, the disease, disorder, or condition associated with DCN-1 and / or DCN-2 overexpression is cancer (e.g., non-small cell lung cancer or gastric cancer).
[0152] In one aspect, Compound 1 and compositions described herein provide treatment of hemoglobinopathies such as sickle cell disorder or disease or thalassemia disorder or disease. In one aspect, Compound 1 and compositions described herein induce HbF (fetal hemoglobin; expressed by the gamma globin genes HBG1 and HBG2). It should be appreciated that induction of HbF allows for the treatment of hemoglobinopathies such as sickle cell disorder or disease or thalassemia disorder or disease. Thus, in one aspect, the disclosure provides Compound 1 and compositions for the treatment of sickle cell disease.
[0153] In one aspect, the disclosure provides Compound 1 and compositions described herein for the treatment of of hemoglobinopathies such as sickle cell disorder or disease or thalassemia disorder or disease In one aspect, Compound 1 and compositions described herein induce HbF (fetal hemoglobin; expressed by the gamma globin genes HBG1 and HBG2) and reduce HbA (adultPage 41 of 114335847364 CENC-013 / 01WO 360899-2047hemoglobin; expressed by the beta globin gene HBB), thus inducing production of fetal hemoglobin and reducing the expression of the hemoglobin beta gene. It should be appreciated that induction of HbF and reduction of HbA allows for the treatment of hemoglobinopathies such as sickle cell disorder or disease or thalassemia disorder or disease. Thus, in one aspect, the disclosure provides Compound 1 and compositions for the treatment of sickle cell disease.
[0154] In some embodiments, Compound 1 and compositions described herein are irreversible covalent inhibitors of DCN- 1 and / or DCN-2. In some embodiments, an irreversible covalent inhibitor of DCN-1 and / or DCN-2 provided herein can be used to treat diseases associated with DCN-1 and / or DCN-2. In some embodiments, an irreversible covalent inhibitor of DCN-1 and / or DCN-2 provided herein can be used to treat sickle cell disease. In some embodiments, a compound described herein is a reversible covalent inhibitor of DCN-1 and / or DCN-2. In some embodiments, a reversible covalent inhibitor of DCN-1 and / or DCN-2 provided herein can be used to treat diseases associated with DCN-1 and / or DCN-2. In some embodiments, a reversible covalent inhibitor of DCN-1 and / or DCN-2 provided herein can be used to treat sickle cell disease. In some embodiments, a compound described herein is a reversible inhibitor of DCN-1 and / or DCN-2. In some embodiments, a reversible inhibitor of DCN-1 and / or DCN-2 provided herein can be used to treat diseases associated with DCN- 1 and / or DCN-2. In some embodiments, a reversible covalent of DCN-1 and / or DCN-2 provided herein can be used to treat sickle cell disease.
[0155] In one aspect, the disclosure provides irreversible covalent inhibitors of DCN-1 and / or DCN-2 for the treatment of a disease, disorder, or condition associated with DCN-1 and / or DCN-2. In some embodiments, the disclosure provides irreversible covalent inhibitors of DCN-1 and / or DCN- 2 for the treatment of sickle cell disease. In some embodiments, the irreversible covalent inhibitors of DCN-1 and / or DCN-2 irreversibly covalently modify a cysteine of DCN-1 and / or DCN-2. In some embodiments, the irreversible covalent inhibitors of DCN-1 and / or DCN-2 irreversibly covalently modify Cysll5 of DCN-1 and / or DCN-2. In some embodiments, the irreversible covalent inhibitor includes a warhead to allow for the covalent modification of DCN-1 and / or DCN-2. In some embodiments the warhead includes a nitrile group. In some embodiments, the warhead does not include a vinyl group.
[0156] In one aspect, the disclosure provides reversible covalent inhibitors of DCN-1 and / or DCN-2 for the treatment of a disease, disorder, or condition associated with DCN-1 and / or DCN-2. In some embodiments, the disclosure provides reversible covalent inhibitors of DCN-1 and / or DCN-2 for thePage 42 of 114335847364 CENC-013 / 01WO 360899-2047treatment of sickle cell disease. Tn some embodiments, the reversible covalent inhibitors of DCN-1 and / or DCN-2 reversibly covalently modify a cysteine of DCN-1 and / or DCN-2. In some embodiments, the reversible covalent inhibitors of DCN-1 and / or DCN-2 reversibly covalently modify Cysll5 of DCN-1 and / or DCN-2. In some embodiments, the reversible covalent inhibitor includes a warhead to allow for the covalent modification of DCN-1 and / or DCN-2. In some embodiments the warhead includes a nitrile group. In some embodiments, the warhead does not include a vinyl group.
[0157] In one aspect, the disclosure provides reversible inhibitors of DCN-1 and / or DCN-2 for the treatment of a disease, disorder, or condition associated with DCN-1 or DCN-2. In one aspect, the disclosure provides reversible inhibitors of DCN-1 and / or DCN-2 for the treatment of sickle cell disease.
[0158] In one aspect, the present disclosure provides a method of treating a hemoglobinopathy disorder or disease, comprising administering to a subject in need thereof Compound 1 or composition thereof disclosed herein, or a pharmaceutically acceptable salt thereof. In another aspect, the present disclosure provides a method of inducing or increasing production of fetal hemoglobin. Such methods are useful, for example, in treating hemoglobin-related disorders including sickle cell disorders, diseases and conditions and thalassemia.
[0159] In some embodiments, the hemoglobinopathy is a sickle cell disorder or disease.
[0160] In some embodiments, the hemoglobinopathy is a thalassemia disorder or disease.
[0161] In one aspect, the present disclosure provides a method to increase red blood cell levels and / or hemoglobin levels in a subject in need thereof, treat or prevent an anemia in a subject in need thereof, treat sickle-cell disease in a subject in need thereof, or treat one or more complications of sickle-cell disease in a subject in need thereof, comprising administering to a subject in need thereof Compound 1 disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with hydroxyurea or a pharmaceutically acceptable salt thereof.
[0162] In one aspect, the present disclosure provides a method to increase fetal hemoglobin levels in a subject in need thereof, treat or prevent an anemia in a subject in need thereof, treat sickle-cell disease in a subject in need thereof, or treat one or more complications of sicklecell disease in a subject in need thereof, comprising administering to a subject in need thereof Compound 1 disclosed herein, or a pharmaceutically acceptable salt thereof, in combination with hydroxyurea or a pharmaceutically acceptable salt thereof.Page 43 of 114335847364 CENC-013 / 01WO 360899-2047
[0163] In some embodiments, the present disclosure provides a method for the treatment of a DCN-1 associated disease. In some embodiments, the present disclosure provides a method for the treatment of a DCN-2 associated disease. In some embodiments, the present disclosure provides a method for the treatment of cancers, premalignant conditions (e.g., hyperplasia, metaplasia, and dysplasia), benign tumors, hyperproliferative disorders, and benign dysproliferative disorders. Such methods comprise the step of administering to a subject in need thereof Compound 1 disclosed herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the cancer is characterized by overexpression of DCN-1 and / or DCN-2.
[0164] In some embodiments, cancers and related disorders that can be treated or prevented by methods disclosed herein include, but are not limited, to the following: a squamous cell carcinoma, a metastatic squamous cell carcinoma, a non-small cell lung carcinoma, a uterine carcino- sarcoma, an embryonal rhabdomyosarcoma, a glioblastoma, a medulloblastoma, an osteosarcoma, or an adrenocortical tumor. In some embodiments, the cancer and related disorders include a cancer of the lung, cervix, ovary, uterus, esophagus, prostate, or head and neck.
[0165] In some embodiments, the cancer of the lung includes a non-small cell lung cancer, including, but not limited to a squamous cell carcinoma, adenocarcinoma, or large cell-undifferentiated carcinoma.
[0166] In some embodiments, cancers and related disorders include a hematological malignancy such as a leukemia, a lymphoma, a myeloma, a multiple lymphoma, a B-cell nonHodgkin’s lymphoma, or an acute myeloid leukemia.
[0167] In some embodiments, the present disclosure provides a method for the treatment of a cancer, including, but not limited to, leukemia, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia, chronic leukemia, chronic myelocytic (granulocytic) leukemia, chronic lymphocytic leukemia, polycythemia vera, Lymphoma, Hodgkin’s disease, non-Hodgkin’s disease, multiple myeloma, Waldenstrom’s macroglobulinemia, heavy chain disease, solid tumors, sarcomas and carcinomas, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing’s tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma,Page 44 of 114335847364 CENC-013 / 01WO 360899-2047sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms’ tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.
[0168] In some embodiments, the present disclosure provides a method for the treatment of leukemia, including, but not limited to, acute leukemia, acute lymphocytic leukemia; acute myelocytic leukemia, including, but not limited to, myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia and myelodysplastic syndrome; chronic leukemia, including, but not limited to, chronic myelocytic (granulocytic) leukemia, chronic lymphocytic leukemia, hairy cell leukemia; polycythemia vera; lymphomas, including, but not limited to, Hodgkin's lymphoma, non-Hodgkin's lymphoma; myeloma, including, but not limited, to smoldering multiple myeloma, nonsecretory myeloma, osteosclerotic myeloma, plasma cell leukemia, solitary plasmacytoma and extramedullary plasmacytoma; Waldenstrom's macroglobulinemia; monoclonal gammopathy of undetermined significance; benign monoclonal gammopathy; heavy chain disease; bone and connective tissue sarcomas, including, but not limited to, bone sarcoma, osteosarcoma, chondrosarcoma, Ewing's sarcoma, malignant giant cell tumor, fibrosarcoma of bone, chordoma, periosteal sarcoma, soft-tissue sarcomas, angiosarcoma (hem an giosarcoma), fibrosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, neurilemmoma, rhabdomyosarcoma, synovial sarcoma; brain tumor, including, but not limited to, glioma, astrocytoma, brain stem glioma, ependymoma, oligodendroglioma, nonglial tumor, acoustic neurinoma, craniopharyngioma, medulloblastoma, meningioma, pineocytoma, pineoblastoma, primary brain lymphoma; breast cancer, including, but not limited to, adenocarcinoma, lobular (small cell) carcinoma, intraductal carcinoma, medullary breast cancer, mucinous breast cancer, tubular breast cancer, papillary breast cancer, Paget's disease, and inflammatory breast cancer; adrenal cancer, including, but not limited to, pheochromocytom and adrenocortical carcinoma; thyroid cancer, including, but not limited to, papillary or follicular thyroid cancer, medullary thyroid cancer and anaplastic thyroid cancer; pancreatic cancer, including, but not limited to, insulinoma, gastrinoma, glucagonoma, vipoma, somatostatin-secreting tumor, and carcinoid orPage 45 of 114335847364 CENC-013 / 01WO 360899-2047islet cell tumor; pituitary cancers, including, but not limited to, Cushing's disease, prolactinsecreting tumor, acromegaly, and diabetes insipius; eye cancer, including, but not limited to, ocular melanoma such as iris melanoma, choroidal melanoma, and cilliary body melanoma, and retinoblastoma; vaginal cancer, including, but not limited to, squamous cell carcinoma, adenocarcinoma, and melanoma; vulvar cancer, including, but not limited to, squamous cell carcinoma, melanoma, adenocarcinoma, basal cell carcinoma, sarcoma, and Paget's disease; cervical cancer, including, but not limited to, squamous cell carcinoma, and adenocarcinoma; uterine cancer, including, but not limited to, endometrial carcinoma and uterine sarcoma; ovarian cancers, including, but not limited to, ovarian epithelial carcinoma, borderline tumor, germ cell tumor, and stromal tumor; esophageal cancer, including, but not limited to, squamous cancer, adenocarcinoma, adenoid cyctic carcinoma, mucoepidermoid carcinoma, adenosquamous carcinoma, sarcoma, melanoma, plasmacytoma, verrucous carcinoma, and oat cell (small cell) carcinoma; stomach cancer, including, but not limited to, adenocarcinoma, fungating (polypoid), ulcerating, superficial spreading, diffusely spreading, malignant lymphom, liposarcoma, fibrosarcoma, and carcinosarcoma; colon cancer; rectal cancer; liver cancer, including, but not limited to, hepatocellular carcinoma and hepatoblastoma, gallbladder cancer, including, but not limited to, adenocarcinoma; cholangiocarcinoma, including, but not limited to, pappillary, nodular, and diffuse; lung cancer, including, but not limited to, non-small cell lung cancer, squamous cell carcinoma (epidermoid carcinoma), adenocarcinoma, large-cell carcinoma and small-cell lung cancer; testicular cancer, including, but not limited to, germinal tumor, seminoma, anaplastic, classic (typical), spermatocytic, nonseminoma, embryonal carcinoma, teratoma carcinoma, and choriocarcinoma (yolk-sac tumor); prostate cancer, including, but not limited to, adenocarcinoma, leiomyosarcoma, and rhabdomyosarcoma; penal cancers; oral cancer, including, but not limited to, squamous cell carcinoma; basal cancers; salivary gland cancer, including, but not limited to, adenocarcinoma, mucoepidermoid carcinoma, and adenoidcystic carcinoma; pharynx cancer, including, but not limited to, squamous cell cancer, and verrucous; skin cancer, including, but not limited to, basal cell carcinoma, squamous cell carcinoma and melanoma, superficial spreading melanoma, nodular melanoma, lentigo malignant melanoma, and acral lentiginous melanoma; kidney cancer, including, but not limited to, renal cell cancer, adenocarcinoma, hypernephroma, fibrosarcoma, and transitional cell cancer (renal pelvis and / or uterer); Wilms’ tumor; bladder cancer, including, but not limited to, transitional cell carcinoma, squamous cell cancer,Page 46 of 114335847364 CENC-013 / 01WO 360899-2047adenocarcinoma, carcinosarcoma. In addition, cancer includes myxosarcoma, osteogenic sarcoma, endotheliosarcoma, lymphangioendotheliosarcoma, mesothelioma, synovioma, hemangioblastoma, epithelial carcinoma, cystadenocarcinoma, bronchogenic carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma and papillary adenocarcinomas.
[0169] In some embodiments, the present disclosure provides a method for the treatment of liver injury. Without being limited to a specific mechanism, targeting neddylation provides a method for the treatment of liver fibrosis and liver injury. (See e.g., Zubiete-Franco et al. Hepatology 65 (2) 2017, 694-709). Thus, in some embodiments, the present disclosure provides a method for the treatment of hepatitis, Non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, cirrhosis, hemochromatosis, jaundice, autoimmune liver disorders, liver cancer, galactosemia, alpha- 1 antitrypsin deficiency, Wilson disease, oxalosis, liver adenoma, Alagille syndrome, primary biliary cholangitis (PBC), and lysosomal acid lipase deficiency (LAL-D).
[0170] In some embodiments, the present disclosure provides a method for the treatment of heart disease. Without being limited to a specific mechanism, targeting neddylation, provides a method for the treatment of heart disease (See e.g., Kandala et al., Am. J. Cardiovasc. Dis 4, 2014, 140). Thus, in some embodiments, the present disclosure provides a method for the treatment of arrhythmia, heart failure, coronary artery disease, heart valve disease, congenital heart disease, angina, cardiomyopathy, pericarditis, peripheral artery disease, aortic aneurysm, aortic stenosis, deep vein thrombosis, Mlarfan syndrome and rheumatic heart disease.
[0171] In some embodiments, the present disclosure provides a method for the treatment of neurodegenerative diseases (See e.g., Villa et al., Eur J. Neurol. 16 (7) 2009, 870. Thus, in some embodiments, the present disclosure provides a method for the treatment of amyotrophic lateral sclerosis, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, multiple system atrophy, tauopathies and prion diseases.
[0172] In some embodiments, the method optionally comprises co-administration of a second therapeutic agent. In some embodiments, the second therapeutic agent is hydroxyurea or a pharmaceutically acceptable salt thereof.
[0173] In one aspect, the present disclosure provides a method of treating a hemoglobinopathy disorder or disease, comprising administering to a subject in need thereof Compound 1, or a pharmaceutically acceptable salt thereof, in combination with a second agent such as hydroxyurea or a pharmaceutically acceptable salt thereof.Page 47 of 114335847364 CENC-013 / 01WO 360899-2047
[0174] In some embodiments, the hemoglobinopathy is a sickle cell disorder or disease.
[0175] In some embodiments, the hemoglobinopathy is a thalassemia disorder or disease.
[0176] In some embodiments, Compound 1 or pharmaceutically acceptable salt thereof and the hydroxyurea or a pharmaceutically acceptable salt thereof act synergistically.
[0177] In one aspect, the present disclosure provides a method of increasing efficacy and / or reducing toxicity of hydroxyurea treatment in a subject undergoing said treatment, comprising administering to the subject Compound 1, or a pharmaceutically acceptable salt thereof. In some embodiments, the hydroxyurea treatment is for a hemoglobinopathy. In some embodiments, the hydroxyurea treatment is for sickle cell disease. In some embodiments, the hydroxyurea treatment is for a thalassemia disorder.
[0178] In some embodiments, the method further comprises the step of decreasing an amount of hydroxyurea being administered to the subject.
[0179] In some embodiments, the amount of hydroxyurea being administered is decreased by 10-90%.
[0180] In one aspect, the present disclosure provides a method of decreasing the dose of hydroxyurea or a pharmaceutically acceptable salt thereof needed for effective treatment of a hemoglobinopathy disorder or disease, comprising administering to a subject in need thereof Compound 1, or a pharmaceutically acceptable salt thereof, in combination with hydroxyurea or a pharmaceutically acceptable salt thereof, wherein the dose of hydroxyurea or a pharmaceutically acceptable salt thereof needed for effective treatment of the hemoglobinopathy disorder or disease is less than the dose needed for treatment in the subject using hydroxyurea or a pharmaceutically acceptable salt thereof as a monotherapy.
[0181] In some embodiments, the dose of hydroxyurea or a pharmaceutically acceptable salt thereof co-administered with Compound 1 or pharmaceutically acceptable salt thereof is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% relative to the dose needed for treatment in the subject using hydroxyurea or a pharmaceutically acceptable salt thereof as a monotherapy.
[0182] In some embodiments, the present disclosure provides a method to treat or prevent one or more complications of sickle cell disease including, for example, anemia, anemia crisis, splenomegaly, pain crisis, chest syndrome, acute chest syndrome, blood transfusion requirement, organ damage, pain medicine (management) requirement, splenic sequestration crises,Page 48 of 114335847364 CENC-013 / 01WO 360899-2047hyperhem olytic crisis, vaso-occlusion, vaso-occlusion crisis, acute myocardial infarction, sicklecell chronic lung disease, thromboemboli, hepatic failure, hepatomegaly, hepatic sequestration, iron overload and complications of iron overload (e.g., congestive heart failure, cardiac arrhythmia, myocardial infarction, other forms of cardiac disease, diabetes mellitus, dyspnea, hepatic disease and adverse effects of iron chelation therapy), splenic infarction, acute and / or chronic D renal failure, pyelonephritis, aneurysm, ischemic stroke, intraparenchymal hemorrhage, subarachnoid hemorrhage, intraventricular hemorrhage, peripheral retinal ischemia, proliferative sickle retinopathy, vitreous hemorrhage, and / or priapism; comprising administering to a subject in need thereof Compound 1 or pharmaceutically acceptable salt thereof, optionally in combination with a second therapeutic agent such as hydroxyurea or a pharmaceutically acceptable salt thereof.Combination Therapies
[0183] Depending upon the particular condition, or disease, to be treated, additional therapeutic agents, which are normally administered to treat that condition, may be administered in combination with formulations comprising Compound 1 described herein. As used herein, additional therapeutic agents that are normally administered to treat a particular disease, or condition, are known as “appropriate for the disease, or condition, being treated.”
[0184] In certain embodiments, a provided combination, or composition thereof, is administered in combination with another therapeutic agent.
[0185] In one aspect, the formulations comprising Compound 1 are used advantageously in combination with a second therapeutic agent. Such a second therapeutic agent includes, in some embodiments, hydroxyurea or a pharmaceutically acceptable salt thereof.
[0186] In some embodiments, the disclosure provides methods for using a compound or combination therapy (for example, formulations comprising Compound 1 or pharmaceutically acceptable salt thereof in combination with hydroxyurea or a pharmaceutically acceptable salt thereof) to treat or prevent vascular occlusion (vaso-occlusion) in a sickle-cell disease patient in need thereof as well as various complications associated with vaso-occlusion in a sickle-cell disease patient (e.g., vaso-occlusion crisis, pain crisis, etc.). In some embodiments, the disclosure provides methods for using formulations comprising Compound 1 or combination therapy to treat or prevent anemia in a sickle-cell disease patient in need thereof as well as various complications associated with anemia in a sickle-cell disease patient (e g., aplastic crisis, hyperhemolytic crisis, etc.).Page 49 of 114335847364 CENC-013 / 01WO 360899-2047
[0187] In such methods, formulations comprising Compound 1 or combination therapy can be used to increase red blood cell levels while reducing the need for red blood cell transfusions and / or iron chelation therapy, and thereby reduce morbidity and mortality associated with iron accumulation in vulnerable tissues / organs. In such methods, formulations comprising Compound 1 or combination therapy can also be used to reduce the need for other supportive therapies for treating sickle-cell disease [e.g., treatment with hydroxyurea, treatment with an EPO or other EPO agonist, and / or pain management (e.g., treatment with one or more of opioid analgesic agents, nonsteroidal anti-inflammatory drugs, and / or corticosteroids)]. In part, formulations comprising Compound 1 or combination therapy can be used in combination with existing supportive therapies for sickle-cell disease including, for example, transfusion of red blood cells, iron chelation therapy, hydroxyurea therapy, EPO or EPO agonist therapy, and / or pain management therapy. Optionally, formulations comprising Compound 1 or combination therapy can be used to reduce the amount, duration, etc. of an existing supportive therapy for sickle-cell disease. For example, while transfusion of red blood cells and iron chelation therapy may help treat certain complications of sickle-cell disease, they sometimes result in adverse side effects. Therefore, in certain aspects, formulations comprising Compound 1 or combination therapy can be used to reduce the amount of a second supportive therapy, e.g., reduce blood cell transfusion burden or reduce the dosage of a chelation therapeutic. In certain aspects, the disclosure provides uses of formulations comprising Compound 1 or combination therapy (optionally in combination with one or more supportive therapies for sickle-cell disease) for making a medicament for the treatment or prevention of sicklecell disease, particularly one or more complications of sickle-cell disease as disclosed herein.
[0188] Those additional agents may be administered separately from a provided combination therapy, as part of a multiple dosage regimen. Alternatively, those agents may be part of a single dosage form, mixed together with a compound of this invention in a single composition. If administered as part of a multiple dosage regime, the two active agents may be submitted simultaneously, sequentially or within a period of time from one another normally within five hours from one another.
[0189] As used herein, the term “combination,” “combined,” and related terms refers to the simultaneous or sequential administration of therapeutic agents in accordance with this invention. For example, a combination of the present invention may be administered with another therapeuticPage 50 of 114335847364 CENC-013 / 01WO 360899-2047agent simultaneously or sequentially in separate unit dosage forms or together in a single unit dosage form.
[0190] The amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent. Preferably the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.
[0191] In one embodiment, the present invention provides a composition comprising Compound 1 and one or more additional therapeutic agents. Such a second therapeutic agent includes, in some embodiments, hydroxyurea or a pharmaceutically acceptable salt thereof.
[0192] The therapeutic agent may be administered together with Compound 1 or may be administered prior to or following administration of Compound 1. Suitable therapeutic agents are described in further detail below. In certain embodiments, Compound 1 may be administered up to 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5, hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, or 18 hours before the therapeutic agent. In other embodiments, Compound 1 may be administered up to 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5, hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, or 18 hours following the therapeutic agent.
[0193] Those additional agents may be administered separately from an inventive compoundcontaining composition, as part of a multiple dosage regimen. Alternatively, those agents may be part of a single dosage form, mixed together with Compound 1 in a single formulation or composition. If administered as part of a multiple dosage regime, the two active agents may be submitted simultaneously, sequentially or within a period of time from one another normally within five hours from one another.
[0194] In those compositions which comprise an additional therapeutic agent, that additional therapeutic agent and Compound 1 may act synergistically. Therefore, the amount of additional therapeutic agent in such compositions will be less than that required in a monotherapy utilizing only that therapeutic agent. In such compositions a dosage of between 0.01 - 1,000 [tg / kg body weight / day of the additional therapeutic agent can be administered.Page 51 of 114335847364 CENC-013 / 01WO 360899-2047
[0195] The amount of additional therapeutic agent present in the compositions comprising Compound 1 will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent. Preferably the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.3. Pharmaceutical Formulation Components
[0196] The compositions of the present invention are administered using any amount and any route of administration effective for treating or lessening the severity of a disease described above. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like. Compound 1 is preferably formulated in unit dosage form for ease of administration and uniformity of dosage. The expression “unit dosage form” as used herein refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific effective dose level for any particular patient or organism (e.g., and feline, canine, bovine, equine, porcine, or aves) will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts.
[0197] Pharmaceutically acceptable compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intraci sternally, intrathecally, transdermally, transmucosally, opthalmically, via inhalation, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), buccally, intranasally, as an oral or nasal spray, or the like, depending on the severity of the disease being treated. In certain embodiments, the compounds of the invention are administered orally or parenterally at dosage levels of about 0.01Page 52 of 114335847364 CENC-013 / 01WO 360899-2047mg / kg to about 50 mg / kg of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
[0198] A unit dosage form of the invention can be formulated for oral administration. Pharmaceutical compositions / formulations that are suitable for oral administration can be provided as discrete dosage forms, such as, but not limited to, tablets, fastmelts, chewable tablets, capsules, pills, strips, troches, lozenges, pastilles, cachets, pellets, medicated chewing gum, bulk powders, effervescent or non-effervescent powders or granules, oral mists, solutions, emulsions, suspensions, wafers, sprinkles, elixirs, and syrups. In some embodiments, such dosage forms contain predetermined amounts of active ingredients, and may be prepared by methods of pharmacy known to those skilled in the art. See generally, Remington’s Pharmaceutical Sciences, 18thed., Mack Publishing, Easton Pa. (1990). As used herein, oral administration also includes buccal, lingual, and sublingual administration.
[0199] In some embodiments, the formulation further comprises one or more pharmaceutically acceptable excipients or carriers.
[0200] A person of ordinary skill would recognize that pharmaceutical formulation ingredients may serve multiple purposes within a formulation. Accordingly, a person of ordinary skill would recognize that certain formulation components may be classified according to multiple functions (e.g., a component may be both a filler and a binder).
[0201] In some embodiments, a unit dosage form provided herein are prepared by combining the active ingredients in an intimate admixture with one or more pharmaceutically acceptable excipients or carriers, including, but not limited to, binders, fillers, diluents, disintegrants, wetting agents, lubricants, glidants, coloring agents, dye-migration inhibitors, sweetening agents, flavoring agents, emulsifying agents, suspending and dispersing agents, preservatives, solvents, nonaqueous liquids, organic acids, and sources of carbon dioxide, according to conventional pharmaceutical compounding techniques. Excipients or carriers can take a wide variety of forms depending on the form of preparation desired for administration. For example, excipients or carriers suitable for use in oral liquid or aerosol dosage forms include, but are not limited to, water, glycols, oils, alcohols, flavoring agents, preservatives, and coloring agents. Examples of excipients or carriers suitable for use in solid oral dosage forms (e.g., powders, tablets, capsules, and caplets) include, but are not limited to, starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrating agents.Page 53 of 114335847364 CENC-013 / 01WO 360899-2047
[0202] In some embodiments, the pharmaceutically acceptable excipients and carriers are selected from fdlers, binders, diluents, disintegrants, glidants, and lubricants.
[0203] In some embodiments, the present invention provides a capsule or tablet which comprises a provided pharmaceutical composition in the form of a solid dosage form. In some embodiments, the present invention provides a capsule. In some embodiments, the present invention provides a tablet.
[0204] In certain embodiments, the dosage form is a tablet, wherein the tablet is manufactured using standard, art-recognized tablet processing procedures and equipment. In certain embodiments, the method for forming the tablets is direct compression of a powdered, crystalline and / or granular composition comprising a solid form provided herein, alone or in combination with one or more excipients or carriers, such as, for example, carriers, additives, polymers, or the like. In certain embodiments, as an alternative to direct compression, the tablets may be prepared using wet granulation or dry granulation processes. In certain embodiments, the tablets are molded rather than compressed, starting with a moist or otherwise tractable material. In certain embodiments, compression and granulation techniques are used.
[0205] In certain embodiments, the dosage form is a capsule, wherein the capsules may be manufactured using standard, art-recognized capsule processing procedures and equipments. In certain embodiments, soft gelatin capsules may be prepared in which the capsules contain a mixture comprising a solid form provided herein and vegetable oil or non-aqueous, water miscible materials, such as, for example, polyethylene glycol and the like. In certain embodiments, hard gelatin capsules may be prepared containing granules of solid forms provided herein in combination with a solid pulverulent carrier, such as, for example, lactose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives, or gelatin. In certain embodiments, a hard gelatin capsule shell may be prepared from a capsule composition comprising gelatin and a small amount of plasticizer such as glycerol. In certain embodiments, as an alternative to gelatin, the capsule shell may be made of a carbohydrate material. In certain embodiments, the capsule composition may additionally include polymers, colorings, flavorings and opacifiers as required. In certain embodiments, the capsule comprises HPMC.
[0206] In some embodiments, the pharmaceutical composition comprises one or more fillers. In certain embodiments, the filler is selected from ammonium aliginate, calcium carbonate, calcium lactate, calcium phosphate, calcium silicate, calcium sulfate, cellulose acetate, compressible sugarPage 54 of 114335847364 CENC-013 / 01WO 360899-2047(eg., lactose, glucose, and sucrose), corn starch, dextrates, erythritol, ethyl cellulose, glyceryl palmitostearate, isomalt, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, mediumchain triglycerides, microcrystalline cellulose, pre-gelatinized starch, polydextrose, polymethacrylates, silicic acid, simethicone, sodium alginate, sodium chloride, sorbitol, starch, sugar spheres, sulfobutylether P-cyclodextrin, talc, tragacanth, trehalose, and xylitol, or a combination thereof.
[0207] In some embodiments, the fdler is selected from talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof.
[0208] In some embodiments, the fdler is microcrystalline cellulose. In some embodiments, the fdler is lactose. In some embodiments, the fdler is starch. In some embodiments, the fdler is a combination of starch and lactose. In some embodiments, the fdler is a combination of lactose and microcrystalline cellulose. In some embodiments, the fdler is a combination of two or three components recited above. In some embodiments, the fdler comprises at least microcrystalline cellulose, lactose, and mannitol.
[0209] In certain embodiments, dosage forms provided herein comprise one or more diluents. Diluents may be used, e.g., to increase bulk so that a practical size tablet or capsule is ultimately provided. Suitable diluents include dicalcium phosphate, calcium sulfate, lactose, cellulose, kaolin, mannitol, sodium chloride, dry starch, microcrystalline cellulose, microfine cellulose, pregelitinized starch, calcium carbonate, calcium sulfate, sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, polymethacrylates, potassium chloride, sodium chloride, sorbitol and talc, among others. Diluents also include, e.g., ammonium alginate, calcium carbonate, calcium phosphate, calcium sulfate, cellulose acetate, compressible sugar, confectioner’s sugar, dextrates, dextrin, dextrose, erythritol, ethylcellulose, fructose, fumaric acid, glyceryl palmitostearate, isomalt, kaolin, lacitol, lactose, mannitol, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium-chain triglycerides, microcrystalline cellulose, microcrystalline silicified cellulose, powered cellulose, polydextrose, polymethylacrylates, simethicone, sodium alginate, sodium chloride, sorbitol, starch, pregelatinized starch, sucrose, sulfobutylether-P-cyclodextrin, talc, tragacanth, trehalose, and xylitol.Page 55 of 114335847364 CENC-013 / 01WO 360899-2047
[0210] In some embodiments, the pharmaceutical composition comprises one or more binders. Binders may be used, e.g., to impart cohesive qualities to a tablet or a capsule, and thus ensure that the formulation remains intact after compression. In some embodiments, the binder is selected from acacia gum, agar, alginic acid, calcium carbonate, calcium lactate, carbomers (e.g., acrylic acid polymer, carboxy polymethylene, polyacrylic acid, carboxyvinyl polymer), carboxymethylcellulose sodium, carrageenan, cellulose acetate phthalate, ceratonia, chitosan, copovidone, corn starch, cottonseed oil, dextrates, dextrin, dextrose, ethylcellulose, gelatin, glyceryl behenate, guar gum, hydrogenated vegetable oil type I, hydroxyethylcellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hypromellose, inulin, lactose, magnesium aluminum silicate, maltodextrin, maltose, methylcellulose, microcrystalline cellulose, pectin, poloxamer, polycarbohil, polydextrose, polyethylene oxide, polymetharylates, polyvinylpyrrolidone, pre-gelatinized starch, povidone, sodium alginate, starch, stearic acid, sucrose, tricaprylin, vitamin E polyethylene glycol succinate, and zein.
[0211] Suitable binders include, but are not limited to, starch (including potato starch, com starch, and pregelatinized starch), gelatin, sugars (including sucrose, glucose, dextrose and lactose), polyethylene glycol, propylene glycol, waxes, and natural and synthetic gums, e.g., acacia sodium alginate, polyvinylpyrrolidone (PVP), cellulosic polymers (including hydroxypropyl cellulose (HPC), hydroxypropylmethylcellulose (HPMC), methyl cellulose, ethyl cellulose, hydroxyethyl cellulose (HEC), carboxymethyl cellulose and the like), veegum, carbomer (e.g., carbopol), sodium, dextrin, guar gum, hydrogenated vegetable oil, magnesium aluminum silicate, maltodextrin, polymethacrylates, povidone, microcrystalline cellulose, among others. Binding agents also include, e.g., acacia, agar, alginic acid, cabomers, carrageenan, cellulose acetate phthalate, ceratonia, chitosan, confectioner’s sugar, copovidone, dextrates, dextrin, dextrose, ethylcellulose, gelatin, glyceryl behenate, guar gum, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hydroxypropyl starch, hypromellose, inulin, lactose, magnesium aluminum silicate, maltodextrin, maltose, methylcellulose, poloxamer, polycarbophil, polydextrose, polyethylene oxide, polymethylacrylates, povidone, sodium alginate, sodium carboxymethylcellulose, starch, pregelatinized starch, stearic acid, sucrose, and zein.
[0212] In some embodiments, the pharmaceutical composition comprises one or more di si nt egrants. In certain embodiments, the disintegrant is selected from alginic acid, calciumPage 56 of 114335847364 CENC-013 / 01WO 360899-2047alginate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, cellulose, chitosan, colloidal silicon dioxide, corn starch, croscarmellose sodium, crospovidone, docusate sodium, glycine, guar gum, hydroxypropyl cellulose, magnesium aluminum silicate, methylcellulose, microcrystalline cellulose, pre-gelatinized starch, polacrilin potassium, povidone, silicates, sodium aliginate, sodium carbonate, and sodium starch glycolate.
[0213] Suitable disintegrants include, but are not limited to, agar; bentonite; celluloses, such as methylcellulose and carboxymethylcellulose; wood products; natural sponge; cation-exchange resins; alginic acid; gums, such as guar gum and Veegum HV; citrus pulp; cross-linked celluloses, such as croscarmellose; cross-linked polymers, such as crospovidone; cross-linked starches; calcium carbonate; microcrystalline cellulose, such as sodium starch glycolate; polacrilin potassium; starches, such as com starch, potato starch, tapioca starch, and pre-gelatinized starch; clays; aligns; and mixtures thereof.
[0214] In some embodiments, the pharmaceutical composition comprises one or more surfactants. In some embodiments, the surfactant is selected from polyoxyethylene (20) sorbitan monolaurate (e.g., Tween-20), polyoxyethylene (20) sorbitan monooleate (e.g., Tween-80), sodium lauryl sulfate, and sodium dodecyl sulfate.
[0215] In some embodiments, the pharmaceutical composition comprises one or more pore formers. In some embodiments, the pore former is selected from hydroxypropylcellulose, hydroxypropylmethylcellulose, polyethyleneglycol, poloaxamer 188, povidone (e.g., Kollidon K25 / K30), or sugar (e.g., glucose, mannose, fructose, and sucrose).
[0216] In some embodiments, the pharmaceutical composition comprises one or more glidants. In some embodiments, the glidant is selected from calcium phosphate, cellulose, colloidal silicon dioxide, fumed silica, magnesium oxide, magnesium silicate, magnesium stearate, magnesium trisilicate, and talc. Suitable glidants include, but are not limited to, colloidal silicon dioxide, CAB-O-SIL™ (Cabot Co. of Boston, MA), and asbestos-free talc.
[0217] In some embodiments, the pharmaceutical composition comprises one or more lubricants. In some embodiments, the lubricant is selected from calcium stearate, glycerin monosterate, glyceryl behenate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, light mineral oil, myristic acid, poloxamer, polyethylene glycol, sodium benzoate, sodium chloride, sodium lauryl sulfate, sodium stearyl fumarate, solid polyethylene glycols, stearic acid, and talc.Page 57 of 114335847364 CENC-013 / 01WO 360899-2047
[0218] Lubricants that can be used in pharmaceutical compositions and dosage forms include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laureate, agar, and mixtures thereof. Additional lubricants include, for example, a syloid silica gel (AEROSIL200, manufactured by W.R. Grace Co. of Baltimore, Md.), a coagulated aerosol of synthetic silica (marketed by Degussa Co. of Plano, Tex.), CAB-O-SIL (a pyrogenic silicon dioxide product sold by Cabot Co. of Boston, Mass.), and mixtures thereof.
[0219] In some embodiments, the pharmaceutical composition comprises one or more film coating agents. In some embodiments, the film coating comprises a poly(vinyl alcohol) base. In some embodiments, the film coating includes a coloring agent or pigment. In some embodiments, the film coating is Opadry II® such as Opadry II® yellow.
[0220] Suitable coloring agents include, but are not limited to, any of the approved, certified, water soluble FD&C dyes, and water insoluble FD&C dyes suspended on alumina hydrate, and color lakes and mixtures thereof. A color lake is the combination by adsorption of a water-soluble dye to a hydrous oxide of a heavy metal, resulting in an insoluble form of the dye.
[0221] Suitable flavoring agents include, but are not limited to, natural flavors extracted from plants, such as fruits, and synthetic blends of compounds which produce a pleasant taste sensation, such as peppermint and methyl salicylate.
[0222] Suitable sweetening agents include, but are not limited to, sucrose, lactose, mannitol, syrups, glycerin, and artificial sweeteners, such as saccharin and aspartame.
[0223] Suitable emulsifying agents include, but are not limited to, gelatin, acacia, tragacanth, bentonite, and surfactants, such as polyoxyethylene sorbitan monooleate (Tween-20), polyoxyethylene sorbitan monooleate 80 (Tween-80), and triethanolamine oleate.
[0224] Suitable suspending and dispersing agents include, but are not limited to, sodium carboxymethylcellulose, pectin, tragacanth, Veegum, acacia, sodium carbomethylcellulose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone.
[0225] Suitable preservatives include, but are not limited to, glycerin, methyl and propylparaben, benzoic acid, sodium benzoate, and alcohol.Page 58 of 114335847364 CENC-013 / 01WO 360899-2047
[0226] Suitable wetting agents include, but are not limited to, propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate, and polyoxyethylene lauryl ether.
[0227] Suitable solvents include, but are not limited to, glycerin, sorbitol, ethyl alcohol, and syrup.
[0228] Suitable non-aqueous liquids utilized in emulsions include, but are not limited to, mineral oil and cottonseed oil.
[0229] Suitable organic acids include, but are not limited to, citric and tartaric acid.
[0230] Suitable sources of carbon dioxide include, but are not limited to, sodium bicarbonate and sodium carbonate.
[0231] The pharmaceutical compositions provided herein for oral administration can be provided as compressed tablets, tablet triturates, chewable lozenges, rapidly dissolving tablets, multiple compressed tablets, or enteric-coating tablets, sugar-coated, or film-coated tablets. Enteric-coated tablets are compressed tablets coated with substances that resist the action of stomach acid but dissolve or disintegrate in the intestine, thus protecting the active ingredients from the acidic environment of the stomach. Enteric-coatings include, but are not limited to, fatty acids, fats, phenyl salicylate, waxes, shellac, ammoniated shellac, and cellulose acetate phthalates. Sugar-coated tablets are compressed tablets surrounded by a sugar coating, which may be beneficial in covering up objectionable tastes or odors and in protecting the tablets from oxidation. Film-coated tablets are compressed tablets that are covered with a thin layer or film of a water-soluble material. Film coatings include, but are not limited to, hydroxy ethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000, and cellulose acetate phthalate. Film coating imparts the same general characteristics as sugar coating. Multiple compressed tablets are compressed tablets made by more than one compression cycle, including layered tablets, and press-coated or dry-coated tablets.
[0232] A tablet dosage form can be prepared from the active ingredient in powdered, crystalline, or granular forms, alone or in combination with one or more carriers or excipients described herein, including binders, disintegrants, controlled-release polymers, lubricants, diluents, and / or colorants.
[0233] A tablet of the present disclosure can be formulated for rapid, sustained, extended, or modified release.Page 59 of 114335847364 CENC-013 / 01WO 360899-2047
[0234] In some embodiments, a unit dosage form of the invention comprises one or more pharmaceutically acceptable excipients selected from microcrystalline cellulose, lactose monohydrate (modified), croscarmellose sodium, hydroxypropyl cellulose, and magnesium stearate.
[0235] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, com, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
[0236] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3 -butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer’s solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.
[0237] Injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
[0238] In order to prolong the effect of a compound of the present invention, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorptionPage 60 of 114335847364 CENC-013 / 01WO 360899-2047of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
[0239] Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compound of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
[0240] The active compound can also be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
[0241] Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, and eye drops are also contemplated as being within the scope of this invention. Additionally, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body. Such dosage formsPage 61 of 114335847364 CENC-013 / 01WO 360899-2047can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
[0242] For oral administration in the form of a tablet or capsule (e.g., a gelatin capsule), the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, magnesium aluminum silicate, starch paste, gelatin, methylcellulose, sodium carboxymethylcellulose and / or polyvinylpyrrolidone, natural sugars such as glucose or beta-lactose, com sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, silica, talcum, stearic acid, its magnesium or calcium salt and / or polyethyleneglycol and the like. Disintegrants include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum starches, agar, alginic acid or its sodium salt, or effervescent mixtures, croscarmellose or its sodium salt, and the like. Diluents include, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and / or glycine.
[0243] Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
[0244] A therapeutically effective dose, of a compound described herein in an oral formulation, may vary from 0.15 mg / kg to 20 mg / kg patient body weight per day, more particularly 0.015 to 1.0 mg / kg, which can be administered in single or multiple doses per day. For oral administration, the drug can be delivered in the form of tablets or capsules containing 1 mg to 100 mg of the active ingredient specifically, 1 mg, 5 mg, 10 mg, 20 mg, 50 mg, or 100 mg, or in the forms of tables orPage 62 of 114335847364 CENC-013 / 01WO 360899-2047capsules containing at least 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50% (w / w) of the active ingredient. For example, the capsules may contain 50 mg of the active ingredient, or 5-10% (w / w) of the active ingredient. For example, the tablets may contain 100 mg of the active ingredient, or 20-50% (w / w) of the active ingredient. For example, the tablet may contain, in addition to the active ingredient, a disintegrant or emollient (e.g., croscarmellose or its sodium salt and methyl cellulose), a diluent (e.g., microcrystalline cellulose), and a lubricant (e.g., sodium stearate and magnesium stearate). The drug can be administered on a daily basis either once, twice or more per day.
[0245] For administration by inhalation, the compounds can be delivered in the form of an aerosol spray from pressured container or dispenser, which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
[0246] For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art. Penetration enhancers promote the penetration of drugs through the corneal barrier and change the integrity of the epithelial cell layer. Frequently used penetration enhancers in ocular formulations include cyclodextrin, dimethyl sulphoxide (DMSO), ethylenediaminetetraacetic acid (EDTA), sodium glycocholate and related cholates, Tween 20 (a non-ionic polysorbate surfactant), Brij 35 (polyoxyethylene lauryl ether), saponins and bile salts. Generally, penetration enhancers such as EDTA and cholates transiently loosen the tight junctions between adjacent cells of the corneal epithelium. Thus, penetration enhancers, when applied topically to the eye, have been successfully applied to the delivery of protein and peptides through the corneal epithelium. In some embodiments, a formulation described herein includes a penetration enhancer such as polyoxyethylene-9-lauryl ether, sodium deoxycholate, sodium glycocholate, or sodium taurocholate.
[0247] In some embodiments, a pharmaceutically acceptable excipient in an ophthalmic solution or transmucosal formulation of the invention is a cyclodextrin. Cyclodextrins are known to act as permeation enhancers and mucoadhesive agents. In some embodiments, the cyclodextrin is a-, flor y-cyclodextrin. In some embodiments, the cyclodextrin is a pharmaceutically acceptablePage 63 of 114335847364 CENC-013 / 01WO 360899-2047derivative of a cyclodextrin, including, but not limited to, the hydroxyalkyl derivatives of a-, 0-and y-cyclodextrin (especially the hydroxyethyl and hydroxypropyl derivatives of 0-cyclodextrin and y-cyclodextrin), randomly methylated 0-cyclodextrin, sulfobutylether 0-cyclodextrin, sulfobutylether y-cyclodextrin, and the so-called branched 0- and y-cyclodextrin derivatives such as glucosyl-0-cyclodextrin and glucosyl-y-cyclodextrin. The natural cyclodextrins are either used alone or in a mixture of two or more cyclodextrins, by way of non-limiting example, a mixture of the y-cyclodextrin and the more water-soluble hydroxypropyl y-cyclodextrin, or y-cyclodextrin and sulfobutylether y-cyclodextrin, or 0-cyclodextrin and hydroxypropyl-0-cyclodextrin, or 0-cyclodextrin and sulfobutyl ether 0-cyclodextrin.
[0248] In some embodiments, a pharmaceutically acceptable excipient in an ophthalmic solution or transmucosal formulation of the invention is sulfobutylether-0-cyclodextrin, in particular at any of the specified concentrations and ranges of concentrations above, such as about 7% w / v. In some embodiments, a pharmaceutically acceptable excipient in an ophthalmic solution of the invention is hydroxypropyl-0-cyclodextrin, in particular at any of the specified concentrations and ranges of concentrations specified above, such as about 7% w / v.
[0249] In some embodiments, an ophthalmic solution of the invention comprises a pharmaceutically acceptable buffering agent. In some embodiments, a pharmaceutically acceptable buffering agent is a phosphate buffer, citrate buffer, tris buffer, histidine buffer or acetate buffer.
[0250] In some embodiments, a pharmaceutically acceptable buffering agent is sodium phosphate, dibasic. In some embodiments, a pharmaceutically acceptable buffering agent is sodium phosphate, monobasic. In some embodiments, a pharmaceutically acceptable buffering agent is a mixture of sodium phosphate, dibasic, and sodium phosphate, monobasic. In some embodiments, an ophthalmic solution of the invention comprises about 0.083% w / v sodium phosphate, dibasic, and about 0.017% w / v sodium phosphate, monobasic.
[0251] In some embodiments, the ophthalmic solution of the invention is at an approximately neutral pH. In some embodiments, an ophthalmic solution of the invention is at a pH of 6.5 to 8. In some embodiments, an ophthalmic solution of the invention is at a pH of 6.9 to 7.7. In some embodiments, an ophthalmic solution of the invention is at a pH of 7.1 to 7.5. In some embodiments, an ophthalmic solution of the invention is at a pH of about 7.3.Page 64 of 114335847364 CENC-013 / 01WO 360899-2047
[0252] Pharmaceutically acceptable acids and / or bases may be used in the ophthalmic solution to adjust pH. In some embodiments, an ophthalmic solution of the invention comprises a pharmaceutically acceptable acid. In some embodiments, an ophthalmic solution of the invention comprises a pharmaceutically acceptable base. In some embodiments, an ophthalmic solution of the invention comprises a pharmaceutically acceptable acid and base. In some embodiments, a pharmaceutically acceptable acid is hydrochloric acid. In some embodiments, pharmaceutically acceptable base is sodium hydroxide.
[0253] In some embodiments, an ophthalmic solution of the invention comprises a tonicity agent. In some embodiments, a tonicity agent is selected from the group consisting of dextrose, potassium chloride, propylene glycol, and sodium chloride. In some embodiments, an ophthalmic solution of the invention comprises a tonicity agent at a concentration of less than about 0.5% w / v. In some embodiments, an ophthalmic solution of the invention comprises a tonicity agent at a concentration of about 0.45%, 0.4%, 0.35%, 0.3%, 0.25%, 0.2%, 0.15%, or 0.1% w / v. In some embodiments, a tonicity agent is sodium chloride.
[0254] Parenteral formulations comprising the compound described herein can be prepared in aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions. The formulations may be sterilized and / or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and / or buffers. In addition, they may also contain other therapeutically valuable substances. The compositions are prepared according to conventional methods, and may contain about 0.1 to 75%, preferably about 1 to 50%, of a compound described herein.
[0255] The phrases “parenteral administration” and “administered parenterally” are art-recognized terms, and include modes of administration other than enteral and topical administration, such as by injection, and include, without limitation, intravenous, intramuscular, intrapleural, intravascular, intrapericardial, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intra-articular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.
[0256] Formulations for topical administration to the skin can include, for example, ointments, creams, gels and pastes comprising the primary amine compound in a pharmaceutical acceptable carrier. The formulation of the primary amine compound for topical use includes the preparation of oleaginous or water-soluble ointment bases, as is well known to those in the art. For example,Page 65 of 114335847364 CENC-013 / 01WO 360899-2047these formulations may include vegetable oils, animal fats, and, for example, semisolid hydrocarbons obtained from petroleum. Particular components used may include white ointment, yellow ointment, cetyl esters wax, oleic acid, olive oil, paraffin, petrolatum, white petrolatum, spermaceti, starch glycerite, white wax, yellow wax, lanolin, anhydrous lanolin and glyceryl monostearate. Various water-soluble ointment bases may also be used, including glycol ethers and derivatives, polyethylene glycols, polyoxyl 40 stearate and polysorbates.
[0257] In some embodiments, the compound or pharmaceutically acceptable salt thereof is administered systemically. In some embodiments, the compound or pharmaceutically acceptable salt thereof is administered orally as part of a solid pharmaceutical composition. In some embodiments, the pharmaceutical composition is a liquid. In some embodiments, the pharmaceutical composition is administered as a liquid via nasogastric tube.
[0258] In some embodiments, the solid form of Compound 1 is substantially amorphous or crystalline, or is a mixture thereof. In some embodiments, the solid form is substantially free of impurities.
[0259] All publications, patents, patent applications and other documents cited in this application are hereby incorporated by reference in their entireties for all purposes to the same extent as if each individual publication, patent, patent application or other document were individually indicated to be incorporated by reference for all purposes.
[0260] All features of each of the aspects of the invention apply to all other aspects mutatis mutandis.
[0261] In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.EXEMPLIFICATIONExample 1: Synthesis of Intermediate Compound 5: rac-N-((4R,5R)-7-ethyl-4-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-l-phenyl-4,5,6,7-tetrahydro-lH-pyrazolo[3,4-b]pyridine-5-yl)-3-(trifluoromethyl)benzamideNMR:Page 66 of 114335847364 CENC-013 / 01WO 360899-2047
[0262] rH NMR spectrum was recorded on Bruker 400 MHz and Varian 400 MHz instruments internally referenced to a tetramethylsilane (TMS) signal. Chemical shifts (8) and coupling constants (J) were expressed in parts per million and hertz, respectively.LCMS:
[0263] Method-A: LCMS_X-Select (Formic acid); Column: X-Select CSH C18 (3.0*50) mm 2.5p; Mobile Phase: A: 0.05% Formic acid in water: I (95:5) B: 0.05% Formic acid in ACN; Inj Volume: 2.0pL, Column oven temperature: 50 C; Flow Rate: 1.2 mL / min. Gradient program: 0% B to 98 % B in 2.0 minute, hold till 3.0 min, at 3.2 min B cone is 0 % up to 4.0 min.
[0264] Method-B: Column: X-Bridge C18 (3.0*50) mm 2.5p; Mobile Phase: A: 2.5 mM Ammonium Bicarbonate in water; B: Acetonitrile; Flow Rate: 1.2 mL / min; Column oven temp.50°C; Gradient program:0% B to 98 % B in 2.0 minute, hold till 3.0 min, at 3.2 min B cone is 0 % up to 4.0 min.
[0265] HPLC:
[0266] Column: X-Bridge CSH C18 (150 X 4.6mm, 3.5pm); Mobile Phase-A: 5mMNH4HCO3 in water; Mobile Phase-B: I; Programme / B%: 0.01 / 2,2 / 2,12 / 90,16 / 90; Flow: 1.0 mL / min.; Diluent: I: WATER (80:20).Synthesis of Intermediate Compound 5Page 67 of 114335847364 CENC-013 / 01WO 360899-2047i ACN, n-BuLi,THF, -78°Cto RT, 12 hImidazole, TBDMSCI,ii PhNHNH2, PhCI, DMF, 0 °C to RT, 16 h \ / Hcr~Y0EtReflux, 140°C, 16 h o Step-1 Step-2 SM-1 1B, PhCI, SnCI2, 150°C, 16 h Step-3
[0267] Step-1: Synthesis of ethyl 2-((tert-butyldimethylsilyl)oxy)acetate (1):
[0268] To stirred solution of compound (SMI) (25 g, 240.1 mmol) in DMF (125 mL) was added imidazole (27.6 g, 312.2 mmol) and TBDMSCI (47.04 g, 312.2 mmol) at OoC. The reaction mixture was stirred at room temperature for 16 h. After consumption of the starting material (by TLC), the reaction mixture was quenched with water (1.2 lit) and extracted with EtOAc (2x500 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated to afford crude compound. The obtained crude compound was purified by using flash column chromatography eluting with 0-20% EtOAc in Heptane. Pure fraction was collected and concentrated under vacuum to afford compound (1) (24 g, 46.1%) as colorless liquid.
[0269] 1HNMR(400 MHz, DMSO-d6): 54.21 (s, 2H), 4.09 (q, J= 6.8 Hz, 2H), 1.18 (t, J= 6.8 Hz, 3H), 0.88 - 0.82 (m, 9H), 0.06 - 0.07 (m, 6H).Page 68 of 114335847364 CENC-013 / 01WO 360899-2047
[0270] Step-(2i): Synthesis of 3-(((tert-butyldimethylsilyl)oxy)methyl)-l-phenyl-lH-pyrazol-5-amine (2A):
[0271] To a stirred solution of acetonitrile (15 mL) in THF (750 mL), n-butyl lithium (2.5 mol / 1) in hexanes (115 ml, 290 mmol) was added at -78° C. The reaction mixture was stirred at -78 oC for 30 min. after 30 mins, compound (1) (40 g, 183.18 mmol) dissolved in THF (750 mL) was added to the reaction mixture slowly at same temperature. Slowly allowed the reaction mixture to room temperature and maintained the same for 12 h. Reaction progress was monitored by TLC. After completion of the reaction, the reaction mixture was quenched with water and adjusted pH to 4-5 using 2N aq.HCl solution. The reaction solution was extracted with 2x500 mL ethyl acetate. Combined organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford crude compound (2A) (37 g, 94.67%) as a pale-brown oil.
[0272] Step-(2ii): Synthesis of 5-[[tert-butyl(dimethyl)silyl] oxymethyl]-2-phenyl-pyrazol-3-amine (2B):
[0273] To a stirred solution of compound (2A) (37 g, 173.42 mmol) in chlorobenzene (110 mL), phenylhydrazine (19 g, 173.94 mmol) was added at room temperature. Raised the reaction mass temperature to 140 oC. The reaction mixture stirred at same temperature for 16 h. Reaction progress was monitored by TLC. After completion of starting material, the reaction mixture was quenched with water (100 mL) and extracted with ethyl acetate (2x500 mL). Combined organic layer was dried over anhydrous sodium sulfate, concentrated under reduced pressure to afford crude compound. The obtained crude compound was purified by column chromatography eluting with 15-20% ethyl acetate in pet ether to afford compound (2B) (26.0 g, 35.07%) as ayellow solid.
[0274] ' H NMR (400 MHz, DMSO-d6): 8 7.54-7.58 (m, 2H), 7.43-7.48 (m, 2H), 7.29 (dt, J = 7.4, 1.2 Hz, 1H), 5.47 (s, 1H), 5.30 (s, 2H), 4.50 (s, 2H), 0.87-0.91 (m, 9H), 0.07 (s, 6H).LC-MS (Method-B) = 304.7 [M+H]+; 70.73 % at RT 2.16 min.
[0275] Step-3: Synthesis of rac-N-((4R,5R)-3-(((tert-butyldimethylsilyl)oxy)methyl)-4-(4-fluorophenyl)-6-oxo-l-phenyl-4,5,6,7-tetrahydro-lH-pyrazolo[3,4-b]pyridine-5-yl)-3-(trifluoromethyl) benzamide (3):
[0276] To a stirred solution compound (2B) (26 g, 85.67 mmol) and Int-B (29.19 g, 85.67 mmol) in chlorobenzene (78 ml), tin (II) chloride (1.64 g, 8.56 mmol) was added at room temperature. The reaction mixture was stirred at 140-150 °C for 16 h. Reaction progress was monitored by TLC. After completion of reaction, the reaction mixture was quenched with water (100 mL) and filtered Page 69 of 114335847364 CENC-013 / 01WO 360899-2047through celite bed and washed with DCM (500 mb). Filtrate was washed with water and extracted with DCM (2x500 mL). Organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained crude was purified by column chromatography by eluting with 20-30% ethyl acetate in pet ether to afford compound (3) (30 g, 48.6 %) as yellow solid.
[0277] rH NMR (400 MHz, DMSO-d6): 5 11.06 (s, 1H), 8.36 (d, J= 3.4 Hz, 1H), 8.07 (s, 2H), 7.89 (d, J= 7.3 Hz, 1H), 7.58-7.71 (m, 4H), 7.49-7.55 (m, 2H), 7.40 (d, J= 6.8 Hz, 1H), 7.03-7.08 (m, 1H), 6.95 (s, 1H), 5.24-5.34 (m, 1H), 4.69 (d, J= 6.8 Hz, 1H), 4.56-4.62 (m, 1H), 4.40-4.46 (m, 1H), 0.73 (s, 5H).
[0278] LC-MS (Method-A) = 639.29 [M+H]+; 88.73 % at RT 2.48 min.
[0279] Step-4: Synthesis of rac-N-((4R,5R)-3-(((tert-butyldimethylsilyl)oxy)methyl)-7-ethyl-4-(4-fluorophenyl)-6-oxo-l-phenyl-4,5,6,7-tetrahydro-lH-pyrazolo[3,4-b]pyridine-5-yl)-3-(trifluoromethyl)benzamide (4):[02S0] To a stirred solution of compound (3) (30 g, 41.33 mmol) in DMF (300 mL), potassium carbonate (7.50 g, 53.73 mmol) and bromoethane (5.45 g, 49.60 mmol) were added at room temperature. The reaction mixture was stirred at room temperature for 16 h. Reaction progress was monitored by TLC. After completion of SM, the reaction mixture was quenched with water and extracted with ethyl acetate. Organic layer was dried over anhydrous sodium sulfate and evaporated under vacuum. The obtained crude was purified by column chromatography by eluting with 15-20% ethyl acetate in heptane to afford compound (4) (15 g, 48.3%) as yellow solid.
[0281] 'H NMR (400 MHz, DMSO-d6) (D2O): 5 8.05-8.10 (m, 2H), 7.91 (d, .7= 7.1 Hz, 1H), 7.68-7.74 (m, 1H), 7.49-7.64 (m, 5H), 7.03-7.10 (m, 2H), 6.90-6.95 (m, 2H), 5.41 (d, J= 7.2 Hz, 1H), 4.65-4.69 (m, 1H), 4.62 (d, J= 12.5 Hz, 1H), 4.45 (d, J= 12.4 Hz, 1H), 2.94-3.08 (m, 2H), 0.79-0.92 (m, 3H), 0.70 (s, 9H), -0.12 (s, 6H).
[0282] LC-MS (Method-B) = 667.5 [M+H]+; 83.38 % at RT 2.52 min.
[0283] Step-5: Synthesis of rac-N-((4R,5R)-7-ethyl-4-(4-fluorophenyl)-3-(hydroxymethyl)-6-oxo-l-phenyl-4,5,6,7-tetrahydro-lH-pyrazolo[3,4-b]pyridine-5-yl)-3-(trifluoromethyl)benzamide (5):
[0284] To a stirred solution of compound (4) (20 g, 24.90 mmol) in acetonitrile (100 mL), hydrochloric acid (20 mL, 120 mmol) was added. The reaction mixture was stirred at room temperature for 16 h. Reaction progress was monitored by TLC. After completion of reaction, the reaction mixture was quenched with ice water (1000 mL) and extracted with ethyl acetate (2x1500Page 70 of 114335847364 CENC-013 / 01WO 360899-2047mL). Organic layer was dried over anhydrous sodium sulfate and concentrated under vacuum to afford crude compound. The crude material was washed with 10% diethyl ether in pentane and dried under vacuum to afford 5 (12.00 g, 83.75%) as a pale-yellow solid.
[0285] 'H NMR (400 MHz, DMSO-d6, 25°C): 8 8.53 (d, J = 13 Hz, 1H), 8.12-8.17 (m, 2H), 7.92 (d, J= 7.8 Hz, 1H), 7.64-7.74 (m, 3H), 7.50-7.61 (m, 3H), 7.10 (t, J= 8.9 Hz, 2H), 6.93-7.05 (m, 2H), 5.50 (t, J = 13 Hz, 1H), 5.1 l(t, J = 6.0 Hz, 1H), 4.72 (d, J = 7.3 Hz, 1H), 4.35-4.41 (m, 1H), 4.24-4.30 (m, 1H), 3.87-3.94 (m, 1H), 2.98-3.08 (m, 1H), 0.91 (t, J= 7.1 Hz, 3H).
[0286] LC-MS (Method-B) = 553.2 [M+H]+; 96.44% at RT 2.26 min.
[0287] HPLC: 95.87 % at RT 9.15 min.Example 2: Synthesis of Compound 1NMR:
[0288] 1H NMR spectrum was recorded on Bruker 400 MHz and Varian 400 MHz instruments internally referenced to a tetramethylsilane (TMS) signal. Chemical shifts (8) and coupling constants (J) were expressed in parts per million and hertz, respectively.LC-MS:
[0289] Method-A: LC-MS_X-Select (Formic acid); Column: X-Select CSH C18 (3.0*50) mm 2.5p.
[0290] Mobile Phase: A: 0.05% Formic acid in water: I (95:5) B: 0.05% Formic acid in ACN.
[0291] Inj Volume: 2.0pL, Column oven temperature: 50 C; Flow Rate: 1.2 mL / min.
[0292] Gradient program: 0% B to 98 % B in 2.0 minute, hold till 3.0 min, at 3.2 min B cone is 0 % up to 4.0 min.
[0293] Method-B: Column: X-Bridge BEH C18, (50mm*3.0mm, 2.5p) Mobile Phase A:2.5mM Ammonium Bicarbonate in Water + 5% I Mobile Phase B: 100% I Flow rate: 1.0 mL / min. Column temperature: 40°C Gradient Program (B%) :0.0 / 2, 0.3 / 2, 2.0 / 98, 2.8 / 98, 3.0 / 2, 3.7 / 2.HPLC:
[0294] Method-A: Column: X Select CSH C18(150 x 4.6) mm,3.5p; Mobile phase A:0.1% FA in Water: I (95:05); Mobile phase B: Acetonitrile; Gradient Programme: T / B% :0.01 / 5, 1 / 5, 8 / 100, 12 / 100, 14 / 5, 18 / 5; Flow rate :1.2 mL / min.Page 71 of 114335847364 CENC-013 / 01WO 360899-2047
[0295] Method-B: Column: X-Bridge CSH Cl 8 (1 0 X 4.6mm, 3.5pm); Mobile Phase-A: 5mM NH4HCO3 in water; Mobile Phase-B: I; Programme / B%: 0.01 / 2,2 / 2,12 / 90,16 / 90; Flow: 1.0 mL / min.; Diluent: I: WATER (80:20).
[0296] Method-C: Column Name: CHIRALPAK-IK (250X4.6mm,5pm) MobilePhase A: n-HEXANE MobilePhase B : ETOH:MEOH(50 / 50) Column ID : M-ARDCAL\OLD-028 Flow rate : l.Oml / min.
[0297] Method-D: Column Name: CHIRALPAK-IC (250X4.6mm,5pm) Column ID : M-ARD-CAL / OLD-005 MobilePhase A : 0.1% DEA n-Hexane MobilePhase B : DCM:IPA (50:50) Flow rate : 1.0 ml / min.
[0298] Method-E: COLUMN: CHIRALPAK-IG (250X4.6mm, 5 gm) M.P-A: n-HEXANE M.P- B : ETOH:MEOH(1:1) A / B : 70 / 30 Flow : 1.0 ml / min.(I) 4M HO Dioxane, RT, 16 h, (II) Chiral-HPLC CNBr, pyridine, DCM, purification 0°C to RT Step-4 Step-5Page 72 of 114335847364 CENC-013 / 01WO 360899-2047
[0299] Step-1: Synthesis of rac-N-((4R,5R)-7-ethyl-4-(4-fluorophenyl)-3-formyl-6-oxo-l-phenyl-4,5,6,7-tetrahydro-lH-pyrazolo[3,4-b]pyridin-5-yl)-3-(trifluoromethyl)benzamide (6):
[0300] To a stirred solution of compound-5 (3.0 g, 5.43 mmol) in DMF (30.0 mL) at 0°C, pyridinium dichromate (2.50 g, 6.51 mmol) was added slowly. The reaction mixture was stirred at 25°C for 16 h. After consumption of the starting material (by TLC), the reaction mixture was quenched with ice cold water (50 mL) and extracted with ethyl acetate (3 x 40 mL). The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude material was purified by medium pressure liquid chromatography by eluting 15- 30% EtOAc / heptane to afford compound (6) (2.20 g, 67%) as an off-white solid.
[0301] 'H NMR (400 MHz, CHLOROFORM-d, 27°C): 59.88 (s, 1H), 8.61 (d, J= 7.2 Hz, 1H), 8.16 - 8.13 (m, 2H), 7.92 - 7.90 (m, 1H), 7.83 -7.82 (m, 2H), 7.72 -7.64 (m, 4H), 7.10 (t, J= 8.4 Hz, 2H), 7.01 (t, J= 5.2Hz, 2H), 5.57 (t, J= 7.2 Hz, 1H), 4.90 (d, J = 7.2 Hz, 1H), 3.91 - 3.85 (m, 1H), 3.05 - 3.00 (m, 1H), 0.89 (t, J= 6.8 Hz, 3H).
[0302] LC-MS (Method-B) = 551.1 [M+H]1; 91.53 % at RT 2.45 min.
[0303] HPLC(Method-B) = 97.30 % at RT 9.32 min.
[0304] Chiral HPLC(Method-C) = Peak-1 : 14.17 % at RT 4.28 min.
[0305] Peak-2: 85.83 % at RT 6.47 min.
[0306] Step-2: Synthesis of N-((4RS,5RS)-3-((E)-(((S)-tert-butylsulfinyl)imino)methyl)-7-ethyl-4-(4-fluorophenyl)-6-oxo-l-phenyl-4,5,6,7-tetrahydro-lH-pyrazolo[3,4-b]pyridin-5-yl)-3-(trifluoromethyl)benzamide (7a):
[0307] To a stirred solution of compound (6) (2.2 g, 4.0 mmol) in THF (22 mL) was added (s)-2-methylpropane-2-sulfinamide (0.97 g, 8.0 mmol) followed by titanium (IV) ethoxide (1.9 g, 8.0 mmol) at 0 °C. The reaction mixture was stirred at 80°C for 16 h. Progress of the reaction was monitored by TLC. After consumption of the reaction, the reaction mixture was poured into ice cold NH4Q solution (150 mL) and extracted with EtOAc (2 x 150 mL). The organic layer was dried over anhydrous Na2SC>4, concentrated under reduced pressure. The crude material was washed with diethyl ether, filtered, and dried to afford compound (7a) (2.70 g, 96.00 %) as an off-white solid.
[0308] ‘HNMR (400 MHz, DMSO-d6) 8 = 8.52 (d, J= 6.4 Hz, 1H), 8.39 (s, 1H), 8.12 - 8.10 (m, 2H), 7.92 (d, J= 7.6 Hz, 1H), 7.83 - 7.81 (m, 2H), 7.72 - 7.62 (m, 4H), 7.10 (t, J= 8.8 Hz,Page 73 of 114335847364 CENC-013 / 01WO 360899-20472H), 6.96 - 6.93 (m, 2H), 5.57 (t, J= 6.8 Hz, 1H), 4.99 (d, J = 7.2 Hz, 1H), 3.90 - 3.88 (m, 1H), 3.04 - 3.02 (m, 1H), 1.17 (s, 9H), 0.94 -0.84 (m, 3H).
[0309] LC-MS (Method-B) = 654.1 [M+H]+; 97.29 % at RT 2.51 min.
[0310] HPLC(Method-B) = 87.97 % at RT 9.60 min.
[0311] Chiral HPLC(Method-C) = 98.99 % at RT 7.60 min.
[0312] Step-3: Synthesis of N-((4RS,5RS)-3-((R)-l-(((S)-tert-butylsulfinyl)amino)ethyl)-7-ethyl-4-(4-fluorophenyl)-6-oxo-l-phenyl-4,5,6,7-tetrahydro-lH-pyrazolo[3,4-b]pyridin-5-yl)-3-(trifluoromethyl)benzamide (7b):
[0313] To a stirred solution of compound (7a) (2.70 g, 4.13 mmol) in DCM (54 mL) was added CHsMgBr (3.0 M in diethyl ether) (4.3 g, 12.4 mmol) at -58°C. Reaction was stirred at same temperature for 1 h and then allowed to room temperature, reaction was stirred for 2 h. After consumption of the starting material (by TLC), the reaction was poured into ice cold NH4CI solution (25 mL) and extracted with DCM (2 x 125 mL). The organic layer was dried over anhydrous Na2SO4, concentrated under reduced pressure. The obtained crude material was washed with diethyl ether to afford (7b) (2.4 g, 69 %) as an off-white solid. Obtained crude material was used for the next step without any further purification.
[0314] ‘H NMR (400 MHz, DMSO-d6) 5 = 8.50 - 8.42 (m, 1H), 8.15 - 8.11 (m, 1H), 7.97 -7.91 (m, 1H), 7.73 - 7.52 (m, 6H), 7.18 - 7.09 (m, 2H), 6.98 - 6.95 (m, 2H), 5.46 (t, J= 7.2 Hz, 1H), 5.17- 5.15 (m, 1H), 4.75 (d, J= 6.8 Hz, 1H), 4.23 -4.19 (m, 2H), 3.90 -3.85 (m, 1H), 3.09 - 3.04 (m, 1H), 1.47 (d, .7= 6.8 Hz, 2H), 1.32- 1.14 (m, 2H), 1.07 - 0.81 (m, 11H).
[0315] LC-MS (Method- A) = 670.39 [M+H]+; 81.08 % at RT 2.48, 2.51 min.
[0316] HPLC(Method-B) = 58.15 % at RT 9.14 min.
[0317] Chiral HPLC(Method-C) = Peak-1 : 87.82% at RT 5.85 min.
[0318] Peak-2: 10.23 % at RT 8.93 min.
[0319] Step-4: Synthesis of N-((4S,5S)-3-((R)-l-aminoethyl)-7-ethyl-4-(4-fluorophenyl)-6-oxo-l-phenyl-4,5,6,7-tetrahydro-lH-pyrazolo[3,4-b]pyridin-5-yl)-3-(trifluoromethyl)benzamide (Compound A):
[0320] To a stirring solution of compound (7b) (2.4 g, 3.3 mmol) in dichloromethane (25 mL) was added (4M Dioxane in HC1, 3.3 mL) at room temperature under inert atmosphere. The reaction mixture was stirred at 25°C for 16 h. Progress of the reaction was monitored by TLC. After consumption of the starting material (by TLC), reaction mixture was concentrated under reducedPage 74 of 114335847364 CENC-013 / 01WO 360899-2047pressure to get crude compound. The Obtained crude compound was purified by Chiral HPLC. Peak-4 from Chiral HPLC was evaporated under reduced pressure to afford compound A (0.7 g, 40 %) as an off-white solid.
[0321] ‘HNMR (400 MHz, DMSO-d6) 8 = 8.53 (d, J= 7.2 Hz, 1H), 8.16 - 8.13 (m, 2H), 7.92 (d, J= 8.0 Hz, 1H), 7.73 - 7.53 ( m, 6H), 7.11 (t, J= 8.8 Hz, 2H), 7.01 - 6.99 (m, 2H), 5.50 (t, J = 7.2 Hz, 1H), 4.71 (d, J= 6.8 Hz, 1H), 4.04 (d, J= 6.0 Hz, 1H), 3.91 - 3.86 (m, 2H), 3.08 - 3.03 (m, 2H), 1.13 - 1.04 (m, 3H), 0.92 (t, J = 6.0 Hz, 3H).
[0322] LC-MS (Method-B) = 566.3 [M+H]+; 83.40 % at RT 2.42 min.
[0323] HPLC(Method-B) = 97.11% at RT 8.75 min.
[0324] Crude Chiral HPLC(Method-D):
[0325] Peak-1 : 8.20% at RT 5.45min. Peak-2: 0.6% at RT 7.47 min.
[0326] Peak-3 :27.89% at RT 9.06 min. Peak-4= 63.22% at RT 11.46 min (desired).
[0327] Step-5: Synthesis of N-((4S,5S)-3-((R)-l-cyanamidoethyl)-7-ethyl-4-(4-fluorophenyl)-6-oxo-l-phenyl-4,5,6,7-tetrahydro-lH-pyrazolo[3,4-b]pyridin-5-yl)-3-(trifluoromethyl)benzamide (Compound 1):
[0328] To a stirring solution of compound (compound A) (Peak-4 from step-4) (350 mg, 0.618 mmol) in dichloromethane (18 mL) were added pyridine (0.14 g, 1.85 mmol) and cyanogen bromide 5M in I (0.24 g, 0.61 mmol) at 0 °C under inert atmosphere. The reaction mixture was stirred at room temperature for 16 h. Progress of the reaction was monitored by LCMS and TLC. After consumption of the starting material (monitored by TLC), the reaction mixture was quenched with ice cold solution of saturated NaHCCh (10 mL), extracted with DCM (2 x 10 mL). The combined organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to get crude compound and was purified by medium pressure liquid chromatography eluting with 0- 45% EA in Heptane, product containing fractions were collected to afford Compound 1 (90.00 mg, 23.8%) as a light brown solid.
[0329] ‘HNMR (400 MHz, DMSO-d6) 88.53 (d, J= 7.2 Hz, 1H), 8.16- 8.13 (m, 2H), 7.92 (d, J= 8.0 Hz, 1H), 7.73 -7.68 (m, 3H), 7.62 -7.52 (m, 3H), 7.26 (d, J= 5.2Hz, 1H), 7.11 (t, .7- 4,8 Hz, 2H), 7.01 - 6.97 (m, 2H), 5.54 (t, J = 7.6 Hz, 1H), 4.67 (d, J = 6.8 Hz, 1H), 4.33 - 4.27 (m, 1H), 3.91 -3.85 (m, 1H), 3.09 - 3.02 (m, 1H), 1.23 - 1.20 (m, 3H), 0.91 (t,J= 7.2 Hz, 3H).
[0330] LC-MS (Method-B) = 591.24 [M+H]+; 98.75 % atRT 2.17 min.
[0331] HPLC(Method-B) = 97.09% at RT 8.91 min.Page 75 of 114335847364 CENC-013 / 01WO 360899-2047
[0332] Chiral HPLC(Method-E) = 99.30 % at RT 5.74 min.
[0333] The sample of Compound 1 received for polymorph screen was amorphous with glass transition temperature of ~96 °C. Polymorph screening was carried out using commonly used solvents and various crystallization methods, including slurry conversion, cooling, evaporation, anti-solvent precipitation and cyclic heating-cooling. A total of six polymorphs were identified, including one anhydrate (Form C), and five solvates or hydrates (Forms A, B and D - F). Among them, Form A and Form C show better solid-state properties than the others. Form A is an isostructural solvate obtained from several solvents and could exist as a channel hydrate after desolvation. Form C is anhydrate but it was only obtained in solvent system containing IPE, likely through desolvation of IPE. DVS result showed that Form A was hygroscopic with reversible water sorption of 0 - 2.6% at RH 0 - 80%, while Form C and amorphous solid were slightly hygroscopic. All the three solid forms (including amorphous) remained unchanged after DVS testing.
[0334] Form C was both physically and chemically stable at 60 °C (capped) and 40 °C / 75%RH (open) for one week and show acceptable solid-state properties and stability. Form C was only obtained in IPE in this work, the slight difference of XRPD pattern between wet and dry sample suggests that Form C might be prepared through desolvation while IPE is not suitable for scale-up.Characterization Data of Compound 1 Form CDSC Endo TGAForm Crystallinity Onset / Pk T Wt.Comment Solvation by XRPD (°C), Loss% / TAH (J / g) (°C)Form C Obtained in solvent High 111 / 118, 15 0.6, 95 - 185Anhydrate system containing IPEPage 76 of 114335847364 CENC-013 / 01WO 360899-2047Item Form CPurity (254 nm) 99.47%XRPD High crystallinityDesolvation (Anhydrate)DSC109 / 119, 14.6 J / gOnset / Peak °C, AH (J / g)TGA0.45% / 85 - 135 °CWt. loss% / @T (°C)DVS (wt. gain%, 80 / 90%RH) 0.5 / 0.6Residual solvent fH-NMR) 0.86% (0.05 eq.) IPE40 °C / 75%RHHPLC PurityUnchanged(1 week) 60 °C / CappedSolid form 40 °C / 75%RHUnchanged(1 week) 60 °C / Capped
[0335] Form C sample was obtained from IPE or mixed solvent system containing IPE.
[0336] Form C sample #1 was characterized by XRPD, PLM, TGA, DSC, 'H-NMR and DVS. XRPD confirmed the sample was Form C with high crystallinity. The sample was irregular shaped crystal under microscope. About 1.60% (0.09 eq.) IPE was detected by 'H-NMR TGA result showed 1.7% weight loss at 95 - 160 °C. DSC curve showed one endothermic peak at 110 °C (onset). Thermal treatment of Form C was performed. After heating to 100 °C and then cooling to RT, the XRPD pattern of Form C remained unchanged. Hence, Form C is postulated to be an anhydrate. DVS result showed that Form C was slightly hygroscopic, and the crystal form remained unchanged after DVS analysis. Form C adsorbed 0.6% moisture at 90% RH.
[0337] Form C was first observed in IPE by slurry study. There was 0.6% weight loss at 95 -185 °C, and one endothermic peak at 111 °C was observed in DSC curve. Hence, a slurry study was conducted for further investigation of Form C. Form C was stirred in PE and H-pentane for 3Page 77 of 114335847364 CENC-013 / 01WO 360899-2047d at RT. Solid sample was collected by fdtration and analyzed by XRPD andJH-NMR. The crystal form of Form C remained unchanged after stirring in PE for 3 d, and the amount of IPE decreased from 2.1% to 0.14%. Hence, Form C is an anhydrate. However, there is still 0.8% wt. loss in TGA curve at 90 - 190 °C.
[0338] Form C was scaled up to 100 mg scale by slurry conversion. About 100 mg of Compound 1 was seeded with 1 -2 mg of Form C and stirred in 3 mb of IPE / Hept (1 / 2, v / v) for 1 day. A sample was collected by fdtration and vacuum dried at 40 °C for 8 h, then analyzed. Form C was prepared successfully with a yield of 74%. Slight differences of XRPD pattern were observed before and after drying of Form C sample, indicating the exists of unstable precursor (solvate / hydrate). Hence, Form C might be prepared through desolvation.Example 4: Development of Formulations of Compound 1
[0339] This API has been developed as three dose strengths: 5 mg, 50 mg and 200 mg.
[0340] The abbreviations used in the examples are as shown in the table below.Abbreviations NameAPI Active Pharmaceutical Ingredient BU Blend UniformityChP Chinese PharmacopoeiaCoA Certificate of AnalysisCU Content UniformityDSC Differential Scanning Calorimetry EC Excipient CompatibilityLDPE Low Density PolyethyleneHOPE High Density PolyethyleneHPC EXF Hydroxypropyl Cellulose Klucel™ EXF PHARM ID IdentificationIID Inactive Ingredient Database IPC In-process ControlPE PolyethylenePage 78 of 114335847364 CENC-013 / 01WO 360899-2047N.D Not DetectedRH Relative HumidityRSD Relative Standard Deviation SD Standard DeviationTGA Thermo Gravimetric Analysis USP United States Pharmacopoeia XRPD X-Ray Powder Diffraction
[0341] Two dissolution methods were used during screening of the development batches. The first method involved screening to simulate the in vivo conditions. The second method was used as the QC method for release / stability testing. This has 0.5% surfactant added to pH 4.5 buffer to achieve sink conditions for the API in the dissolution media. Different crystalline forms of API and excipients were used to prepare formulations. Based on the powder properties data of different formulations, the flowability of lubricated blend showed no significant change among all three formulations and all formulations met the requirements of automatic capsule filling. The dissolution data showed that the release with different crystalline forms of API was comparable within 255 minutes.
[0342] The formulation compositions of F25 / F70 are presented in Table 1. The wet granulation process parameters of F25 / F70 are presented in Table 2.Table 1: Formulation composition - F25 / F70Process Wet granulation + Capsule fdling Form. No. F25 F70 Ingredient w / w % mg / unit w / w % mg / unit Intra-granularCompound 1 (milled Form C 55.60 50.00 55.60 50.00 Lactose Monohydrate Granulac®17.72 15.95 N / A N / A 200Mannitol PEARLITOL 50C N / A N / A 19.20 17.30 Microcry stalline Cellulose17.72 15.95 19.20 17.30 VIVAPUR® 101Page 79 of 114335847364 CENC-013 / 01WO 360899-2047Process Wet granulation + Capsule filling Form. No. F25 F70 Ingredient w / w % mg / unit w / w % mg / unit Croscarmellose Sodium3.00 2.70 N / A N / A VIVASOL®Sodium Starch GlycolateN / A N / A 3.00 2.70 VIVASTAR® PBinder SolutionHydroxypropyl Cellulose Klucel™2.00 1.80 N / A N / A EXF PHARMPremium LV HydroxypropylN / A N / A 2.00 1.80 Methylcellulose E5Sodium Laury l Sulfate Kolliphor®3.00 2.70 N / A N / A SLS FinePurified Water N / A 20.7 N / A 20.7Extra-granularMagnesium Stearate LIGAMED1.00 0.90 1.00 0.90 MF-2-V-MBTotal Weight* 100.00 90.00 100.00 90.00Capsule S lellEmpty7Hard Gelatin Capsules, 4#rich yellow opaque (cap color code:1 capsule 38.00 N / A N / A 41.878, body color code: 41.878) - CN, USEmpty Hard Gelatin Capsules, 3#white opaque (cap color code:N / A N / A 1 capsule 48.00 44.801, body color code: 44.801) - CN, US*Note: The total weight does not include the weight of purified water.Table 2: Process parameters - wet granulation of F25 / F70Page 80 of 114335847364 CENC-013 / 01WO 360899-2047Items Actual ParametersForm. No. F25 F70Granulating Solvent Water WaterSolid content ofHydroxypropylCellulose EXF / 7.14 % 8 %Premium LVHydroxypropylMethylcellulose E5Milling of wet granules 18 Mesh 18 MeshDrying temperature 50°C 50°CDrying time 40 min 30 minMilling of dry granules 24 Mesh 24 MeshLOD 2.65 % 2.37 %
[0343] The powder properties for granules of F25 / F70 are shown in Table 3. Based on the powder properties data, compared to F25, the flowability of F70 lubricated blend is better, but the bulk and tapped densities are slightly lower.Table 3: Powder properties -F25 / F70Bulk Density Tapped Density Carr IndexForm. No.g / ml g / ml %F25 0.380 0.519 26.8 F70 0.326 0.419 22.2
[0344] Dissolution results of F25 / F70 are shown in Table 4. The dissolution data showed that the F70 formulation dissolved rapidly than F25 and 10% higher release at the end point. Therefore, the excipients used in F70 were selected for further development.Table 4: Dissolution results - F25 / F70FeSSIF-pH5.0-Paddle-75 rpmForm.(Infinity rotating speed 250 rpm during 240-255 min)No.Dissolution (%)Page 81 of 114335847364 CENC-013 / 01WO 360899-2047Time5 10 15 30 45 60 120 180 240 255 (min)VI 30 33 35 41 46 50 57 62 66 66 F25 V2 20 28 31 37 41 44 52 57 60 62 Mean 25 31 33 39 44 47 54 59 63 64 VI 14 24 32 40 48 51 63 67 72 74 V2 22 32 37 46 51 56 66 72 76 78 F70 V3 26 34 39 48 53 57 66 72 76 78 Mean 21 30 36 45 50 55 65 70 75 77 RSD 29.6 17.1 9.2 8.6 5.1 6.2 3.2 3.8 2.7 2.7
[0345] Based on F70, the binder level was adjusted from 2% to 3% to improve the granulation efficiency and content weight was increased from 90 mg to 100 mg to prepare F82 formulation. The final blend was filled in size 3 capsules instead of size 4 for previous batches. The formulation compositions of F70 / F82 are presented in Table 5. The critical wet granulation process parameters of F70 / F82 are presented in Table 6.Table 5: Formulation composition - F70 / F82Process Wet granulation + Capsule filling Form. No. F70 F82 Ingredient w / w % mg / unit w / w % mg / unit Intra-granularCompound 1 (milled Form C) 55.60 50.00 50.00 50.00 Mannitol PEARLITOL 50C 19.20 17.30 21.50 21.50 Microcrystalline Cellulose VIVAPUR® 101 19.20 17.30 21.50 21.50 Sodium Starch Glycolate3.00 2.70 3.00 3.00 VIVASTAR® PBinder SolutionPremium LV Hydroxypropyl Methylcellulose E5 2.00 1.80 3.00 3.00 Purified Water N / A 20.70 N / A 34.50Extra-granularMagnesium Stearate LIGAMED MF-2-V-MB 1.00 0.90 1.00 1.00 Total Weight* 100.00 90.00 100.00 100.00Page 82 of 114335847364 CENC-013 / 01WO 360899-2047Process Wet granulation + Capsule filling Form. No. F70 F82 Ingredient w / w % mg / unit w / w % mg / unit Capsule ShellEmpty Hard Gelatin Capsules, 3# white opaque (cap color 1 148.00 48.00 code: 44.801, body color code: 44.801) -CN, US capsule capsule *Note: The total w eight does not include the weight of purified water.Table 6: Process parameters - wet granulation of F25 / F70Items Actual ParametersForm. No. F70 F82Granulating Solvent Water WaterSolid content ofPremium LV8 % 8 %HydroxypropylMethylcellulose E5Milling of wet granules 18 Mesh 18 MeshDrying temperature 50°C 50°CDrying time 30 min 45 minMilling of dry granules 24 Mesh 24 MeshLOD 2.37 % 1.37 %
[0346] The powder properties for granules of F70 / F82 are shown in Table 7. Based on the powder properties data, the flowability of F70 and F82 had no significant difference.Table 7: Powder properties - F70 / F82Bulk Density Tapped Density Carr IndexForm. No.g / ml g / ml %F70 0.326 0.419 22.2 F82 0.318 0.402 20.9
[0347] Dissolution results of F70 / F82 are shown in Table 8. The dissolution data showed that the F82 formulation dissolved rapidly than F70 and 10% higher release rate at the end point. It was Page 83 of 114335847364 CENC-013 / 01WO 360899-2047assumed that the higher dissolution is due to precipitation inhibitor effect of Hypromellose. Therefore, binder level of 3% was selected for better dissolution. Finally, F82 was selected as the target formulation for 50 mg strength.Table 8: Dissolution results - F70 / F82FeSSIF-pH5.0-Paddle-75 rpm(Infinity rotating speed 250 rpm during 240-255 min)Form.Dissolution (%)No.Time5 10 15 30 45 60 120 180 240 255 (min)VI 14 24 32 40 48 51 63 67 72 74 V2 22 32 37 46 51 56 66 72 76 78 F70 V3 26 34 39 48 53 57 66 72 76 78 Mean 21 30 36 45 50 55 65 70 75 77 RSD 29.6 17.1 9.2 8.6 5.1 6.2 3.2 3.8 2.7 2.7 VI 21 34 41 52 59 64 75 80 84 85 V2 25 36 43 53 59 64 75 83 83 85 F82 V3 23 35 42 52 58 64 74 80 83 85 Mean 23 35 42 52 59 64 75 81 84 85 RSD 8.3 2.8 1.8 1.6 0.9 0.6 0.7 2.1 0.5 0.3
[0348] Based on F82, the same formulation composition was selected to prepare formulation for 5 mg strength. The API amount was adjusted with the appropriate diluent levels. The formulation compositions of F86 are presented in Table 9. The critical wet granulation process parameters of F86 are presented in Table 10.Table 9: Formulation composition - F86Process Wet granulation + Capsule filling Form. No. F86Ingredient w / w % mg / unit Intra-granularCompound 1 (milled Form C) 5.00 5.00 Mannitol PEARLITOL 50C 44.00 44.00Page 84 of 114335847364 CENC-013 / 01WO 360899-2047Process Wet granulation + Capsule filling Form. No. F86Ingredient w / w % mg / unit Microcrystalline Cellulose VIVAPUR® 101 44.00 44.00 Sodium Starch Glycolate3.00 3.00 VIVASTAR® PBinder SolutionPremium LV Hydroxypropyl Methylcellulose3.00 3.00E5Purified Water N / A 34.50Extra-granularMagnesium Stearate LIGAMED MF-2-V-MB 1.00 1.00Total Weight* 100.00 100.00Capsule ShellEmpty Hard Gelatin Capsules, 3# white opaque(cap color code: 44.801, body color code: 1 capsule 48.0044.801) -CN. US*Note: The total weight does not include the weight of purified water.Table 10: Wet granulation of F86Items Actual ParametersForm. No. F86Granulating Solvent WaterSolid content of Premium LV8 %Hydroxypropyl Methylcellulose E5Milling of wet granules 18 MeshDrying temperature 50°CDrying time 30 minMilling of dry granules 24 MeshLOD 1.84 %Page 85 of 114335847364 CENC-013 / 01WO 360899-2047
[0349] The powder properties for granules of F86 are shown in Table 11. Based on the powder properties data, the flowability of F86 lubricated blend was acceptable, which can meet the requirements of capsule filling.Table 11: Powder properties -F86Bulk Density Tapped Density Carr IndexForm. No.g / ml g / ml %F86 0.299 0.388 22.9
[0350] Dissolution results of F86 are shown in Table 12. The dissolution data showed that the F86 formulation dissolved rapidly and released completely after 30 minutes in the release medium. Therefore, F86 formulation with empty hard gelatin capsules, 3# was selected as the target formulation for 5 mg strength.Table 12: Dissolution results - F86pH 4.5 acetate buffer+0.5%CTAB-Paddle-75 rpmForm. (Infinity rotating speed 250 rpm during 60-75 min)No. Dissolution (%)Time (min) 5 10 15 30 45 60 75 VI 46 90 98 100 101 101 101 V2 47 89 94 97 98 98 99 F86 V3 60 93 96 105 100 101 102Mean 51 91 96 101 99 100 101 RSD 15.3 2.0 2.3 4.0 1.7 1.7 1.5 Note: the dissolution met rod of fol owing development was transferred from dissolution method 1 to method 2.Example 5: Process Development of Formulations of Compound 1
[0351] This drug product was prepared by wet granulation and capsule filling process. Process development of 3 dose strengths (50 mg and 200 mg capsules are manufactured using a common blend) were performed with typical parameters to study the effect on powder properties and capsules dissolution to evaluate the scalability of the process.Page 86 of 114335847364 CENC-013 / 01WO 360899-2047
[0352] The information of API and excipients is presented in Table 13.Table 13: Information of API and excipientsIngredients Grade Function Supplier Compound 1 (milled Form C) N / A APIMannitol PEARLITOL 50C 50C Diluent Roquette Freres Microcellulose Microcrystalline Cellulose101 Diluent Weissenbom GmbH + VIVAPUR& 101Co. KG Sodium Starch Glycolate CHP Carbohydrate Pima VIVASTAR P DisintegrantVIVASTAR® P GmbH & CO. KG Hydroxypropyl Methylcellulose Nutrition & Biosciences (LV)E5 BinderMETHOCEL™ E5 Premium LV USA 1, LLC Magnesium Stearate LIGAMED LIGAMED MF-2-V- Peter Greven Nederland LubricantMF-2-V-MB MB C.V. Empty Hard Gelatin Capsules, 3# rich yellow opaque3# rich yellow opaque (cap color (cap color code : 41.813,code : 41.813 , body color code : body color code:41.813) -CN, US 41.813) -CN, USEmpty Hard Gelatin Capsules, 3# white opaque (cap3# white opaque (cap color code: color code: 44.808, Capsule Suzhou Capsugel Co., 44.808, body color code: 44.808) body color code: shell Ltd-CN. US 44.808) -CN. USEmpty Hard Gelatin Capsules, 00# rich yellow opaque00# rich yellow opaque (cap (cap color code: 41.813,color code: 41.813, body color body color code:code: 41.813) -CN, US 41.813) -CN, USOral Solid Pharmacal45 ml Sanner Pharmacal & HDPE Bottle 45mlMedical Packaging Oral Solid Preparation PP Child- PackageMaterials (Kunshan) Co. Resistant Assemble Closure CRC33-4Ltd.CRC33-4Page 87 of 114335847364 CENC-013 / 01WO 360899-2047Ingredients Grade Function Supplier PE Bottles Desiccant for SolidShanghai Yingqi Pharmaceutical Preparation Ig / pack DesiccantDesiccant Co., Ltd. Ig / pack- English Printed
[0353] The composition of Compound 1 Drug Product in 5 mg and 50 / 200 mg dosages, are presented in Tables 14 and 15.Table 14: Formulation composition (5 mg)Strength: 5mgTheoreticalComposition w / w% 4500 Function weight Zgcapsulesmg / unitIntra-granularCompound 1 (milled Form C)*15.00 5.00 22.50 API Mannitol PEARLITOL 50C*244.00 44.00 198.00 Diluent Microcrystallinc Cellulose VIVAPUR®44.00 44.00 198.00 Diluent 101Sodium Starch Glycolate3.00 3.00 13.50 Disintegrant VIVASTAR® PBinder SolutionPremium LV Hydroxypropyl3.00 3.00 13.50 Binder Methylcellulose E5Granulation Purified Water*3N / A 34.50 155.25Aid Extra-granularMagnesium Stearate LIGAMED MF-2- 1.00 1.00 4.50 Lubricant V-MBTotal Weight* 100.00 100.00 450.00 N / A Capsule ShellEmpty Hard Gelatin Capsules, 3# richyellow opaque (cap color code: 41.813, 1 CAP 48.00 N / A Capsules shell body color code:Page 88 of 114335847364 CENC-013 / 01WO 360899-2047Strength: 5mgTheoreticalComposition w / w% 4500 Function weight / gcapsulesmg / unit41.813) -CN, USNote:* 1. Theoretical Target Weight of Compound 1 = Theoretical Batch Weight / Assay / (1 -Water content) / (1 -Residual solvent).*2. Mannitol PEARLITOL 50C weight is adjusted to maintain a constant batch weight. Target Weight of Mannitol PEARLITOL 50C = Theoretical Weight of Mannitol PEARLITOL 50C - [Theoretical Target Weight of Compound 1 (A) - Theoretical Batch Weight of Compound 1]*3. The total weight does not include the weight of purified water.Table 15: Formulation composition (50 mg / 200 mg)mg / unitStrength: Strength:Theoretical Composition w / w% 50 mg 200 mg Function weight / g2500 2400capsules capsulesIntra-granularCompound 1 (milled Fomi50.00 50.00 200.0 605.00 API C)*1Mannitol PEARLITOL 50C*221.50 21.50 86.00 260.15 Diluent Microcrystalline Cellulose21.50 21.50 86.00 260.15 Diluent VIVAPUR® 101Sodium Starch Glycolate3.00 3.00 12.00 36.30 Disintegrant VIVASTAR® PBinder SolutionPremium LV Hydroxypropyl3.00 3.00 12.00 36.30 Binder Methylcellulose E5Granulation Purified Water N / A 34.50 138.00 417.45AidPage 89 of 114335847364 CENC-013 / 01WO 360899-2047mg / unitStrength: Strength:Theoretical Composition w / w% 50 mg 200 mg Function weight / g2500 2400capsules capsulesExtra-granularMagnesium Stearate1.00 1.00 4.00 12.10 Lubricant LIGAMED MF-2-V-MBTotal Weight*3100.00 100.00 400.00 1210.00 N / A Capsule ShellEmpty Hard Gelatin Capsules,3# white opaque (cap color1 CAP 48.00 N / A N / Acode: 44.808, body color code:44.808) -CN, USCapsules Empty Hard Gelatin Capsules.shell 00# rich yellow opaque (capcolor code: 41.813, body color 1 CAP N / A 118.00 N / Acode:41.813) -CN, USNote:* 1. Theoretical Target Weight of Compound 1 = Theoretical Batch Weight / Assay / (1 -Water content) / (1 -Residual solvent).*2. Mannitol PEARLITOL 50C weight is adjusted to maintain a constant batch weight. Target Weight of Mannitol PEARLITOL 50C = Theoretical Weight of Mannitol PEARLITOL 50C - [Theoretical Target Weight of Compound 1 (A) - Theoretical Batch Weight of Compound 1]*3. The total weight does not include the weight of purified water.*4. 50 mg and 200 mg use common blend.
[0354] The API and excipients were weighed according to the batch quantities.ScreeningPage 90 of 114335847364 CENC-013 / 01WO 360899-2047
[0355] Mannitol, API, sodium starch glycolate and microciystalline cellulose were screened through the 40 mesh screen in turn and recorded as “mixture 1”. Magnesium stearate was screened through the 40 mesh screen separately.Wet GranulationBinder Solution Preparation
[0356] Under stirring state, the weighed hydroxypropyl methylcellulose was added slowly to purified water to prepare 8.0% w / w binder solution.Dry Mixing
[0357] ‘ ‘Mixture 1” was transferred into a high shear wet granulation pot and dry mixing for 20 minutes was performed. The impeller speed was set to 250 rpm and the chopper speed to 600 rpm. The samples of weight from 96 mg - 288 mg were collected at 10 minutes, 15 minutes and 20 minutes for blend uniformity (BU) testing. The blend uniformity results of dry mixing are presented in Tables 16 and 17.Table 16: 5 mg BU results (dry mixing)Strength Sample Name Mixing time Assay (%) Avg. (%) %Diff %RSD Sample 1 142.3 34.8Sample 2 101.1 -6.4 Sample 3 99.7 -7.810 min 107.5 15.9 Sample 4 99.9 -7.6 Sample 5 102.1 -5.4 Sample 6 100.1 -7.5 Sample 7 106.0 4.3 5 mg Sample 8 101.2 -0.5Sample 9 101.8 0.015 min 101.7 2.1 Sample 10 100.4 -1.4 Sample 11 101.0 -0.7 Sample 12 100.1 -1.7 Sample 13 113.2 10.7 Sample 14 20 min 100.2 102.5 -2.3 5.1 Sample 15 100.7 -1.8Page 91 of 114335847364 CENC-013 / 01WO 360899-2047Strength Sample Name Mixing time Assay (%) Avg. (%) %Diff %RSD Sample 16 100.6 -1.9 Sample 18 100.2 -2.3 Sample 19 100.1 -2.4Table 17: 50 mg / 200 mg BU results (dry mixing)Strength Sample Name Mixing time Assay (%) Avg. (%) %Diff %RSD Sample Al 104.1 0.3Sample A2 105.7 1.9Sample A3 104.5 0.710 min 103.8 1.2 Sample A4 102.9 -0.9Sample A5 102.3 -1.5Sample A6 103.0 -0.8Sample A7 102.6 2.0Sample A8 98.0 -2.6Sample A9 104.4 3.850 mg / 200 mg 15 min 100.6 3.3Sample A10 103.9 3.3Sample Al l 97.7 -2.9Sample A 12 97.2 -3.4Sample A13 104.5 1.9Sample A 14 103.0 0.4Sample Al 5 103.2 0.620 min 102.6 1.9 Sample A16 101.8 -0.8Sample Al 7 99.2 -3.4Sample Al 8 104.0 1.4
[0358] The BU results for 5mg batch showed that sampling location ‘ 1 ’ were significantly higher in dry mixing. The blend uniformity results of dry mixing for 50 and 200 mg common blend were acceptable. The average values met the requirements (RSD<5.0%) at 10, 15 and 20 minutes for all dose strengths.SprayingPage 92 of 114335847364 CENC-013 / 01WO 360899-2047
[0359] The impeller speed is set to 250 rpm and the chopper speed to 1 00 rpm. The binder solution using peristaltic pump was sprayed in an atomized form and the spraying time was recorded. After spraying, the weighed supplemented water was added into the wet granulation pot and the spraying time was recorded.Wet Massing
[0360] The impeller speed is set to 250 rpm and the chopper speed to 1500 rpm, then wet massing for 2 minutes was performed.Wet Milling
[0361] Wet milling using co-mill equipped with 6.0 x 6.0 mm square shaped screen was performed.Drying
[0362] The milled wet granules were transferred into the fluid bed dryer, and drying was performed.Dry Milling
[0363] Dry milling using co-mill equipped with 1.0 mm round shaped screen was performed.Lubrication and BU testing
[0364] The dry granules were loaded into the bin blender. Some dry granules of weight approximately 3 times of that of magnesium stearate from bin blender were added to the PE bag of magnesium stearate with a scoop, mixed for about 20 seconds and transferred back into the bin, then blended at 20.0 rpm for 5 minutes to get a lubricated blend.
[0365] Samples (between 100.0 mg to 300.0 mg in weight) in duplicate were taken after lubrication. The samples were collected into blend uniformity sample bottles for blend uniformity testing.
[0366] After sampling, about 30 g lubricated blend was collected for powder properties test. The powder properties data of lubricated blend was presented in Tables 18 and 19. Then the materials were collected from the blender and the lubricated blend was weighed.Page 93 of 114335847364 CENC-013 / 01WO 360899-2047
[0367] The above data indicated that the blend uniformity results of lubricated blend met the requirements (RSD<5.0%). Therefore, the blending time of 5 minutes at 20.0 rpm was selected for lubrication.Table 18: Bulk / tapped density, angle of reposeTapped CarrForm. Batch Bulk Density Angle of Repose Density IndexNo. No. (g / ml) (°)(g / ml) (%)A 0.347 N / A N / A N / A F94B 0.407 0.522 22.0 35.419C 0.273 N / A N / A N / A F95 / F96D 0.400 0.500 20.0 36.834Table 19: Particle size distributionParameters: Frequency: 100 Hz; Times: 500Ratio (%)Screen Mesh Particle Size RangeF94 F95 / F96>24 Mesh >850 pm 0.2 0.124-50 Mesh 355-850 pm 18.0 7.850-65 Mesh 250-355 pm 11.2 13.465-80 Mesh 180-250 pm 12.5 20.080-100 Mesh 150-180 pm 13.7 16.9100-120 Mesh 125-150 pm 11.5 10.2Capsule Filling120-150 Mesh 90-125 pm 21.9 22.6
[0368] 5 mg strength (F94):<150 Mesh <90 pm 11.0 9.0The lubricatedblend was filled into empty hard gelatin capsules, 3# rich yellow opaque (cap color code: 41.813, body color code: 41.813)-CN, US by encapsulation tray. The fill weight is 100 mg for 5 mg strength.
[0369] The lubricated blend for 50 mg and 200 mg capsules were subdivided and filled. 50 mg strength (F95): The lubricated blend was filled into empty hard gelatin capsules, 3# white opaque Page 94 of 114335847364 CENC-013 / 01WO 360899-2047(cap color code: 44.808, body color code: 44.808)-CN, US by encapsulation tray. The fdl weight is 100 mg for 50 mg strength. 200 mg strength (F96): The lubricated blend was filled into empty hard gelatin capsules, 00# rich yellow opaque (cap color code: 41.813, body color code: 41.813)-CN, US by encapsulation tray. The fill weight is 400 mg for 200 mg strength.
[0370] To evaluate the encapsulation processibility of 5 mg lubricated blend by automatic encapsulation machine, encapsulation was performed. The parameters and acceptable range are presented in Table 20.Table 20: Acceptable criteria of capsule fill weight (machine filling) Item ParameterEncapsulation Plate model #3Dosator model #3Filling speed (cap. / min) 50Filling position 2 3 4 5 6 Filling depth (mm) 0 0 0 0 17.0-17.5 Feeding method ManualItem Range Value Average weight of 20 capsuleN / A 48.4 mg shellsIndividual capsule filling weight* A=100.0 mg / Average content 100.0 mg Target individual filled capsuleA + Average capsule shell weight 148.4 mg weightTarget 10 filled capsule weight (A + Average capsule shell weight) x 10 1484 mg Target 10 filled capsule weight [A x (100%±3.0%) + Average capsule shell 1454 mg - 1514 range weight] x 10 mg Target individual filled capsule [A x (100%±7.5%) + Average capsule shell 140.9 mg - 155.9 weight range weight] mg Locked length of #3 capsule shell 15.9±0.3mm 15.6 - 16.2 mm Note:* 1. The average content of lubricated blend is 102.4%, which is larger than 100 %, no correction was performed.Content UniformityPage 95 of 114335847364 CENC-013 / 01WO 360899-2047
[0371] During the start, middle and end stages of capsule filling, 3 capsules, 4 capsules and 3 capsules were taken respectively to test stratified content uniformity (CU). The CU results are presented in Table 21.Table 21: CU results of capsule filling - F94Batch No. 49099-020-94-5mg-CAPSamples Content% Weight (mg) Samples Content% Weight (mg) CAP-1 104.5 151.12 CAP-6 103.9 150.33 CAP-2 102.3 148.88 CAP-7 105.1 151.87 CAP-3 102.4 146.89 CAP-8 104.4 151.72 CAP-4 101.4 148.07 CAP-9 101.4 144.88 CAP-5 106.2 152.11 CAP- 10 101.0 147.57 Average (%) 103.3 RSD (%) 1.7SD 1.8 AV (USP) 6.0
[0372] Based on the above data, capsule filling process is feasible.Stability Study
[0373] 5 mg and 200 mg strength capsules were selected for stability study.Dissolution Results
[0374] The dissolution results of process development batch are presented in Table 22.Table 22: Dissolution resultspH4.5 acetate buffer+0.5%CTAB-Paddle-75 rpm (Infinity rotating speed 250 rpm during 60-75 min) Strength Condition Dissolution (%) (n=3)Time (min) 5 10 15 20 30 45 60 75 Mean 53 95 98 99 100 100 101 101 InitialRSD 4.0 0.8 1.7 1.6 2.0 1.7 1.9 1.5 Mean 58 95 98 99 100 101 101 101 5 mg 5±3°C. 32daysRSD 7.9 1.8 1.6 1.1 1.0 0.8 0.8 0.4 25°C / 60%RH, Mean 54 92 96 98 99 99 100 10015 days RSD 19.5 1.5 1.4 1.3 1.4 1.1 1.3 1.3Page 96 of 114335847364 CENC-013 / 01WO 360899-2047pH4.5 acetate buffer+0.5%CTAB-Paddle-75 rpm (Infinity rotating speed 250 rpm during 60-75 min) Strength Condition Dissolution (%) (n=3)Time (min) 5 10 15 20 30 45 60 75 25°C / 60%RH. Mean 60 96 99 100 101 101 101 10232days RSD 9.7 1.0 0.1 0.4 0.4 0.4 0.4 0.4 25°C / 60%RH, Mean 53 94 99 100 102 103 103 1033M RSD 29.5 0.5 1.0 1.3 1.5 1.3 1.6 1.2 40°C / 75%RH, Mean 60 95 98 98 99 100 100 10015 days RSD 11.4 1.0 1.3 1.3 1.4 1.6 1.6 1.7 40°C / 75%RH, Mean 57 93 98 99 100 101 101 10232days RSD 18.7 2.0 1.2 1.5 2.0 2.0 1.6 2.1 40°C / 75%RH, Mean 49 93 98 100 101 102 102 1033M RSD 15.3 0.5 0.9 1.3 1.2 1.4 1.0 1.3 40°C / 75%RH, Mean 42 87 95 97 99 100 100 10032daysRSD 14.0 0.9 2.6 2.5 2.5 2.3 2.0 2.0 (No desiccant)Mean 41 70 85 92 99 103 104 105 50 mg InitialRSD 27.9 10.6 4.5 3.9 1.8 0.6 0.4 0.9 Mean 31 63 76 83 92 97 99 102 InitialRSD 10.7 4.6 2.2 1.5 2.1 1.3 1.4 1.5 Mean 32 67 82 90 96 102 103 104 5±3°C. 32daysRSD 12.7 2.0 1.8 2.2 1.4 1.8 2.2 1.9 25°C / 60%RH, Mean 22 64 77 87 97 101 104 10515 days RSD 29.2 6.9 3.5 1.4 2.7 0.8 2.1 1.2 200 mg 25°C / 60%RH, Mean 36 70 84 92 100 105 106 10732days RSD 15.4 4.4 2.9 2.2 1.9 1.7 1.1 0.7 25°C / 60%RH, Mean 25 62 78 86 95 101 103 1053M RSD 7.4 3.0 1.1 1.0 1.0 1.0 0.5 0.3 40°C / 75%RH, Mean 34 69 80 88 96 101 103 10315 days RSD 0.1 0.8 1.1 1.7 1.9 1.6 2.6 2.8 40°C / 75%RH. Mean 30 62 76 84 91 97 100 102Page 97 of 114335847364 CENC-013 / 01WO 360899-2047pH4.5 acetate buffer+0.5%CTAB-Paddle-75 rpm (Infinity rotating speed 250 rpm during 60-75 min) Strength Condition Dissolution (%) (n=3)Time (min) 5 10 15 20 30 45 60 75 32days RSD 11.8 5.2 2.2 1.7 1.4 0.8 1.0 0.3 40°C / 75%RH, Mean 28 61 76 85 94 101 103 1053M RSD 4.3 3.8 2.3 0.7 0.6 0.3 0.6 0.5 40°C / 75%RH, Mean 31 64 77 86 94 100 102 10432daysRSD 8.1 2.6 2.4 2.6 2.5 1.9 2.5 2.5 (No desiccant)
[0375] The dissolution data of 3 months’ stability study under all conditions showed that capsules for all 3 strengths dissolved rapidly and released completely after 45 minutes in the release medium.Related Substance Results
[0376] The related substance results of process development batch are presented in Table 23.Table 23: Related substance resultsRRT0.83Strength Condition 0.89 0.94 1.43 1.44 Total IMP (%Area) (1)Impurity) %Area)Initial 0.11 <LOQ 0.08 0.09 0.28 0.565±3°C, 32days 0.12 <LOQ 0.06 0.11 0.30 0.59 25°C / 60%RH,15days 0.11 <LOQ 0.12 0.09 0.27 0.59 25°C / 60%RH,32days 0.13 <LOQ 0.11 0.09 0.28 0.61 25°C / 60%RH,3M 0.13 <LOQ 0.16 0.10 0.30 0.695 mg40°C / 75%RH,15days 0.13 <LOQ 0.09 0.10 0.29 0.60 40°C / 75%RH,32days 0.14 <LOQ 0.10 0.10 0.30 0.63 40°C / 75%RH,3M 0.16 <LOQ 0.11 0.10 0.30 0.67 40°C / 75%RH,32days0.27 0.05 0.12 0.10 0.29 0.82(No desiccant)Page 98 of 114335847364 CENC-013 / 01WO 360899-2047RRT0.83Strength Condition 0.89 0.94 1.43 1.44 Total IMP (%Area) (1)Impurity(%Area)50 mg Initial 0.10 <LOQ 0.10 0.09 0.28 0.57Initial 0.10 <LOQ 0.17 0.09 0.29 0.655±3°C, 32days 0.11 0.05 0.17 0.10 0.29 0.71 25°C / 60%RH,15days 0.11 <LOQ 0.17 0.10 0.29 0.65 25°C / 60%RH,32days 0.11 <LOQ 0.17 0.09 0.29 0.65 25°C / 60%RH,3M 0.11 <LOQ 0.17 0.10 0.29 0.67200 mg40°C / 75%RH,15days 0.11 <LOQ 0.18 0.09 0.28 0.66 40°C / 75%RH,32days 0.12 <LOQ 0.14 0.09 0.28 0.62 40°C / 75%RH,3M 0.13 <LOQ 0.18 0.09 0.29 0.69 40°C / 75%RH,32days0.14 0.05 0.20 0.10 0.29 0.77(No desiccant)
[0377] The related substance results of stability study showed that the impurity at RRT 0.83 for 5 mg capsules had significantly increased after 32 days under 40°C / 75%RH without desiccant and after 3 months under 40°C / 75%RH with desiccant. There was no marked change for 5 mg and 200 mg capsules with desiccant after 3 months under other conditions.Assay Results
[0378] The assay results of process development batch are presented in Table 24.Table 24: Assay resultsStrength Condition Assay (%) Avg (%)103.1Initial 102.7102.3101.65±3°C. 32days 99.95 mg 98.1104.125°C / 60%RH, 15 days 103.0101.925°C / 60%RH, 32 days 102.0 102.4Page 99 of 114335847364 CENC-013 / 01WO 360899-2047102.8102.725°C / 60%RH, 3M 102.7 / 101.340°C / 75%RH, 15 days 101.1101.0103.140°C / 75%RH, 32 days 103.1103.1104.040°C / 75%RH, 3M 104.0 / 40°C / 75%RH, 32 days 101.6102.2(No desiccant) 102.8104.950 mg Initial 104.7104.6105.6Initial 105.6105.6103.85±3°C, 32days 104.8105.9103.225°C / 60%RH, 15 days 104.0104.8103.025°C / 60%RH, 32 days 103.6104.2103.8200 mg 25°C / 60%RH, 3M 103.8 / 103.340°C / 75%RH, 15 days 102.6101.9102.940°C / 75%RH, 32 days 103.4103.9102.540°C / 75%RH, 3M 102.5 / 40°C / 75%RH, 32 days 103.8104.1(No desiccant) 104.5Page 100 of 114335847364 CENC-013 / 01WO 360899-2047
[0379] The results showed that the 5 mg and 200 mg capsules had no significant change in assay after 3 months under all conditions.Water Content Results
[0380] The water content results of process development batch are presented in Table 25.Table 25: Water content resultsStrength Condition water content (%) Ave (%)1.37152Initial 1.41.522451.315585±3°C, 32days 1.41.569741.3681225°C / 60%RH, 15 days 1.31.308441.1073225°C / 60%RH, 32 days 1.11.169551.508665 mg 25°C / 60%RH, 3M 1.51.538451.2750940°C / 75%RH, 15 days 1.31.282741.2368140°C / 75%RH, 32 days 1.21.176051.6746940°C / 75%RH, 3M 1.71.7147240°C / 75%RH, 32 days 2.241982.2(No desiccant) 2.075930.8828850 mg Initial 0.90.926141.13232Initial 1.11.09598200 mg 0.880415±3°C. 32days 0.90.9219825°C / 60%RH, 15 days 0.92294 0.9Page 101 of 114335847364 CENC-013 / 01WO 360899-20470.953270.7918525°C / 60%RH, 32 days 0.80.802741.2483225°C / 60%RH, 3M 1.21.247660.9630040°C / 75%RH, 15 days 1.00.962430.8718640°C / 75%RH, 32 days 0.90.834351.3643840°C / 75%RH, 3M 1.31.2352540°C / 75%RH, 32 days 1.196381.2(No desiccant) 1.14488
[0381] The water content results showed that the water content for 5 mg capsules had significantly increased after 32 days under 40°C / 75%RH without desiccant, and no significant change was observed for 5 mg and 200 mg capsules after 3 months under both stability conditions.Process Parameters Summary
[0382] Based on the study results of the process development batch, the process parameters are summarized in Table 26.Table 26: Process parameter summary of Drug product capsulesProcessProcess Step Process Variables Acceptable Criteria ParametersCompound 1 40 meshMannitol PEARLITOL 50C 40 meshMicrocrystalline Cellulose 101 40 meshSodium Starch Glycolate VIVASTAR40 meshScreening P N / A Premium LV Hydroxypropyl40 meshMethylcellulose E5Magnesium Stearate LIGAMED MF- 40 mesh2-V-MBPage 102 of 114335847364 CENC-013 / 01WO 360899-2047ProcessProcess Step Process Variables Acceptable Criteria ParametersImpeller Speed 250 rpmDry Mixing Chopper Speed 600 rpmDry mixing Time 20 minImpeller Speed 250 rpmSpraying 1 Chopper Speed 1500 rpm(Binder Solution) Pump Speed 100 rpmTube #19WetImpeller Speed 250 rpm N / A Granulation Spraying 2Chopper Speed 1500 rpm(SupplementedPump Speed 100 rpmWater)Tube #19Impeller Speed 250 rpmChopper Speed 1500 rpmWet MassingWet Massing2 minTimeMilling Speed 5.0 HzWet Milling N / A Milling Mesh 6.0x6.0 mmInlet Air Temp 40 - 60 °CAir Flow Rate 40-100 m3 / hDrying Vibration Frequency 0.6 s N / A Vibration Interval 15 sVibration Time 8 sMilling Speed 5.0 HzDry Milling N / A Milling Mesh 1.0 mmRSD < 5%.Difference of Individual Lubrication Blender Speed x Blending Time 20 rpm x 5 minand Average is within ±10% IndividualCapsule A = 100 mg -x5 mg Capsule Content A x (100% ± 7.5%) Filling Average ContentWeightPage 103 of 114335847364 CENC-013 / 01WO 360899-2047ProcessProcess Step Process Variables Acceptable Criteria ParametersLocked Length 15.6 - 16.2 mm 15.9 ± 0.3 mm IndividualA = 100 mg +Capsule Content A x (100% ± 7.5%) 50 mg Average ContentWeightLocked Length 15.6 - 16.2 mm 15.9 ± 0.3 mm IndividualA = 400 mg <- Capsule Content A x (100% ± 5%) 200 mg Average ContentWeightLocked Length 23.0 - 23.6 mm 23.3 ± 0.3 mm Quantities of capsules and Quantities 10 capsules / bottle 10 capsules / bottle Packagingof desiccant in bottles 1 desiccant / bottle 1 desiccant / bottleExample 6: Batch Formulations of Compound 1
[0383] These formulations were manufactured using process parameters based on results from the process development batches and subjected to stability as per ICH to support the drug product shelflife and storage condition. The process flow diagram of demo batch is presented in FIG. 3.Formulation Composition
[0384] The composition of Compound 1 Drug Product in 5 mg and 50 / 200 mg dosages, are presented in Tables 27 and 28.Table 27: Formulation composition (5 mg)Theoretical Batch mg Weight / g Ingredient w / w % / capsule (5 mg: 6,000 capsules) Intra-granularCompound 1 milled 5.0 5.0 30.0 Mannitol PEARLITOL® 50C 44.0 44.0 264.0 Microcrystalline Cellulose VIVAPUR® 101 44.0 44.0 264.0 Sodium Starch Glycolate VIVASTAR® P 3.0 3.0 18.0Page 104 of 114335847364 CENC-013 / 01WO 360899-2047Binder SolutionHydroxypropyl Methylcellulose METHOCEL™ E53.0 3.0 18.0 Premium LVPurified Water*1N / A q.s. q.s.Extra-granularMagnesium Stearate LIGAMED MF-2-V-MB 1.0 1.0 6.0In Total*2100.0 100.0 600.0Capsule ShellEmpty Hard Gelatin Capsules, 3# rich yellow opaque1(cap color code: 41.813, body color code: 41.813)- 48.0 288.0capsuleCN.USIn Total N / A 148.0 N / A Note:* 1. Used to prepare binder solution, will be removed during drying process.*2. The total weight doesn't include the weights of purified water.Table 28: Formulation composition (50 mg and 200 mg)mg / capsule Theoretical Batch Weight / g (50 mg: 4,000 Ingredient w / w % 50 200capsules; mg mg200 mg: 4,000 capsules) Intra-granularCompound 1 milled 50.0 50.0 200.0 1000.0 Mannitol PEARLITOL® 50C 21.5 21.5 86.0 430.0 Microcrystalline Cellulose VIVAPUR® 101 21.5 21.5 86.0 430.0 Sodium Starch Glycolate VIVASTAR® P 3.0 3.0 12.0 60.0Binder SolutionHydroxypropyl Methylcellulose METHOCEL™ E53.0 3.0 12.0 60.0 Premium LVPurified Water*1N / A q.s. q.s. q.s.Extra-granularPage 105 of 114335847364 CENC-013 / 01WO 360899-2047Magnesium Stearate LIGAMED MF-2-V-MB 1.0 1.0 4.0 20.0In Total*2100.0 100.0 400.0 2000.0Capsule ShellEmpty Hard Gelatin Capsules, 3# white opaque (cap 148.0 N / A 192.0 color code: 44.801, body color code: 44.801)-CN,US capsuleEmpty Hard Gelatin Capsules, 00# rich yellow1opaque (cap color code: 41.813, body color code: N / A 118.0 472.0capsule41.813)-CN,USIn Total N / A 148.0 518.0 N / A Note:* 1. Used to prepare binder solution, will be removed during drying process.*2. The total weight doesn’t include the weights of purified water.
[0385] The API and excipients were weighed according to the batch quantities.
[0386] Data indicated that the blend uniformity results of lubricated blend met the requirements (RSD<5.0%).Related Substance Results
[0387] The related substance results showed that the impurities for capsules of all 3 dose strengths had no significant difference.Assay Results
[0388] The assay results of demo batches ranged from 97.4 to 100.8% and were considered acceptable.Water Content Results
[0389] The results showed that the water content for capsules of the three dose strengths had no significant difference.Page 106 of 114335847364 CENC-013 / 01WO 360899-2047
Claims
CLAIMSWe claim:A pharmaceutical composition comprising:(a) Compound 1:or a pharmaceutically acceptable salt thereof;(b) one or more diluents;(c) one or more disintegrants;(d) one or more binders; and(e) one or more lubricants.
2. The pharmaceutical composition of claim 1, further comprising one or more surfactants.
3. The pharmaceutical composition of claim 1 or 2, wherein the diluent comprises mannitol and microcrystalline cellulose.
4. The pharmaceutical composition of any one of claims 1-3, wherein the disintegrant comprises a pharmaceutically acceptable salt of starch glycolate.
5. The pharmaceutical composition of any one of claims 1-4, wherein the binder comprises hydroxypropyl methylcellulose.
6. The pharmaceutical composition of any one of claims 1-5, wherein the lubricant comprises stearic acid or a pharmaceutically acceptable salt thereof.Page 107 of 114335847364 CENC-013 / 01WO 360899-20477. The pharmaceutical composition of any one of claims 2-6, wherein the surfactant comprises sodium lauryl sulfate.
8. The pharmaceutical composition of any one of claims 1-7, comprising about 5 mg of Compound 1 or a pharmaceutically acceptable salt thereof.
9. The pharmaceutical composition of any one of claims 1-7, comprising about 50 mg of Compound 1 or a pharmaceutically acceptable salt thereof.
10. The pharmaceutical composition of any one of claims 1-7, comprising about 200 mg of Compound 1 or a pharmaceutically acceptable salt thereof.
11. The pharmaceutical composition of any one of claims 1-10, comprising about 44 mg each of a first and a second diluent.
12. The pharmaceutical composition of any one of claims 1-10, comprising about 21.5 mg each of a first and a second diluent.
13. The pharmaceutical composition of any one of claims 1-10, comprising about 86 mg each of a first and a second diluent.
14. The pharmaceutical composition of any one of claims 11-13, wherein the diluent comprises mannitol and microcrystalline cellulose.
15. The pharmaceutical composition of any one of claims 1-14, comprising about 3 mg of disintegrant.
16. The pharmaceutical composition of any one of claims 1-14, comprising about 12 mg of disintegrant.Page 108 of 114335847364 CENC-013 / 01WO 360899-204717. The pharmaceutical composition of claim 15 or 16, wherein the disintegrant comprises a pharmaceutically acceptable salt of starch glycolate.
18. The pharmaceutical composition of any one of claims 1-17, comprising about 3 mg of binder.
19. The pharmaceutical composition of any one of claims 1-17, comprising about 12 mg of binder.
20. The pharmaceutical composition of claims 18 or 19, wherein the binder comprises hydroxypropyl methylcellulose.
21. The pharmaceutical composition of any one of claims 1-20, comprising about 1 mg of lubricant.
22. The pharmaceutical composition of any one of claims 1-20, comprising about 4 mg of lubricant.
23. The pharmaceutical composition of claim 21 or 22, wherein the lubricant comprises stearic acid or a pharmaceutically acceptable salt thereof.
24. The pharmaceutical composition of claim 1 or 2, comprising:(a) about 1-7 mg of Compound 1 or a pharmaceutically acceptable salt thereof;(b) about 35-70 mg of a first diluent comprising mannitol;(c) about 35-70 mg of a second diluent comprising microcrystalline cellulose;(d) about 1-10 mg of a disintegrant comprising a pharmaceutically acceptable salt of starch glycolate;(e) about 1-10 mg of a binder comprising hydroxypropyl methylcellulose; and (f) about 0.5-5 mg of a lubricant comprising stearic acid or a pharmaceutically acceptable salt thereof.Page 109 of 114335847364 CENC-013 / 01WO 360899-204725. The pharmaceutical composition of claim 1 or 2, comprising:(a) about 1-10% w / w of Compound 1 or a pharmaceutically acceptable salt thereof; (b) about 30-60% w / w of a first diluent comprising mannitol;(c) about 30-60% w / w of a second diluent comprising microcrystalline cellulose; (d) about 1-10% w / w of a disintegrant comprising a pharmaceutically acceptable salt of starch glycolate;(e) about 1-10% w / w of a binder comprising hydroxypropyl methylcellulose; and (f) about 0.5-10% w / w of a lubricant comprising stearic acid or a pharmaceutically acceptable salt thereof.
26. The pharmaceutical composition of claim 1 or 2, comprising:(a) about 20-70 mg of Compound 1 or a pharmaceutically acceptable salt thereof; (b) about 15-50 mg of a first diluent comprising mannitol;(c) about 15-50 mg of a second diluent comprising microcrystalline cellulose;(d) about 1-10 mg of a disintegrant comprising a pharmaceutically acceptable salt of starch glycolate;(e) about 1-10 mg of a binder comprising hydroxypropyl methylcellulose; and (f) about 0.5-5 mg of a lubricant comprising stearic acid or a pharmaceutically acceptable salt thereof.
27. The pharmaceutical composition of claim 1 or 2, comprising:(a) about 20-70% w / w of Compound 1 or a pharmaceutically acceptable salt thereof; (b) about 10-40% w / w of a first diluent comprising mannitol;(c) about 10-40% w / w of a second diluent comprising microcrystalline cellulose; (d) about 1-10% w / w of a disintegrant comprising a pharmaceutically acceptable salt of starch glycolate;(e) about 1-10% w / w of a binder comprising hydroxypropyl methylcellulose; and (f) about 0.5-10% of a lubricant comprising stearic acid or a pharmaceutically acceptable salt thereof.
28. The pharmaceutical composition of claim 1 or 2, comprising:Page 110 of 114335847364 CENC-013 / 01WO 360899-2047(a) about 100-300 mg of Compound 1 or a pharmaceutically acceptable salt thereof; (b) about 70-180 mg of a first diluent comprising mannitol;(c) about 70-180 mg of a second diluent comprising microcrystalline cellulose;(d) about 5-25 mg of a disintegrant comprising sodium starch glycolate;(e) about 5-25 mg of a binder comprising hydroxypropyl methylcellulose; and (f) about 2-25 mg of a lubricant comprising magnesium stearate.
29. The pharmaceutical composition of any one of claims 24-28, comprising the following %w / w and mg / unit of ingredients shown below:mg / unitIngredient %w / w5 mgIntra granularCompound 1 5.0 5.0Mannitol 44.0 44.0Microcrystalline Cellulose 44.0 44.0Sodium Starch Glycolate 3.0 3.0Binder SolutionHydroxypropyl3.0 3.0MethylcelluloseExtra granularMagnesium Stearate 1.0 1.0Total 100.0 100.0Capsule ShellEmpty Hard Gelatin1 CAP 48.00Capsules, 3#30. The pharmaceutical composition of any one of claims 24-28, comprising one of the following %w / w and mg / unit of ingredients shown below:Page lll of 114335847364 CENC-013 / 01WO 360899-2047mg / unitIngredient w / w %50 mg 200 mgIntra granularCompound 1 50.0 50.0 200.0Mannitol 21.5 21.5 86.0Microcrystalline21.5 21.5 86.0CelluloseSodium Starch Glycolate 3.0 3.0 12.0Binder SolutionHydroxypropyl3.0 3.0 12.0MethylcelluloseExtra granularMagnesium Stearate 1.0 1.0 4.0Total 100.0 100.0 400.0Capsule ShellEmpty Hard Gelatin1 CAP 48.00 N / ACapsules, 3#Empty Hard Gelatin1 CAP N / A 118.00Capsules, 00#31. A method of producing a pharmaceutical composition, formulation, or unit dosage form, the method comprising wet granulation of a mixture comprising Compound 1:Page 112 of 114335847364 CENC-013 / 01WO 360899-2047or a pharmaceutically acceptable salt thereof;and one or more lubricants.
32. A method of producing a pharmaceutical composition, formulation, or unit dosage form, the method comprising the steps of(1) dry mixing Compound 1:or a solvate or a pharmaceutically acceptable salt thereof, and one or more intragranular excipients;(2) preparing a binder solution;(3) assembling an intragranular phase by wet granulation;(4) dry granulating the mixture; and(5) blending the dry granulate with one or more extragranular excipients.
33. The method of claim 32, wherein step (3) further comprises the use of a granulation aid.
34. The method of claim 33, wherein the granulation aid is water.Page 113 of 114335847364 CENC-013 / 01WO 360899-2047
